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Nasopharyngeal cancer (NPC) is a commonly occurring cancer in the Southern 
Chinese population and affects a relatively young and economically productive 
population. Radiotherapy is the standard treatment for this cancer and weight loss 
is observed in almost all patients during radiotherapy treatment. The determinants 
of weight change, and its short term and long-term impact, have potential 
‘ implications in planning interventions. However, little information is available on 
these issues. 
The objectives of this study are (1) to document the body weight profile and 
various nutritional parameters of NPC patients during and soon after radiotherapy, 
(2) to investigate the potential determinants of weight change , and (3) to assess any 
impact of the short term weight alteration on long term cancer outcome. 
These objectives are investigated by first a retrospective study on a cohort of 386 
NPC patients regarding the determinants, of local-regional recurrence, distant 
recurrence and cancer-related survival at 5-year follow-up, by univariate and 
multivariate analysis. It documented that significant weight loss was common upon 
completion of radiotherapy (with a mean percentage weight loss of 6.6 %, and with 
26% of patients having a weight loss of >10%). On multivariate analysis, a >10% 




A prospective study was conducted on 38 NPC patients to look into the details of 
weight alteration from the beginning and up to 6 months after radiotherapy, and the 
potential determinants of weight alterations. Body weight, body composition, 
dietary record, BMR，physical activity questionnaire and subjective assessment of 
treatment-induced symptoms were assessed. A subset of 11 patients underwent 
additional assessment at more time points and cytokine assessment. It was found 
that 87% of patients experienced >5% body weight loss at the end of radiotherapy, 
without significant recovery up to 6-month after radiotherapy. There was no evidence 
of increase in energy expenditure in terms of BMR per kg body weight and TEE. 
« 
Loss of body weight by the end of radiotherapy correlated with the percentage 
change in calorie intake. Reduction in calorie intake was accompanied by reduced 
protein intake, and presence of radiotherapy-induced symptoms. Calorie intake 
showed significant recovery at two months after radiotherapy, but not accompanied 
by body weight recovery. The weight recovery at 6 months was correlated with the 
calorie density intake and energy balance at end RT. 
V 
Changes in serum leptin level paralleled the change in body fat mass, and there was 
no increase in TNF-a levels at time of maximal weight loss at the end of 
radiotherapy. The data suggest that the patients did not have adequate calorie intake 
during, at completion of, and soon after radiotherapy to obtaining positive energy 
balance. Therefore, monitoring energy expenditure together with nutritional 
intervention to restore any nutritional inadequacies and institute additional nutritional 
support measures during and after radiotherapy may minimize weight loss and favor 
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Chapter 1 Introduction 
Nasopharyngeal cancer (NPC) is a commonly occurring cancer in Hong Kong and 
other regions of Southern China. Incidences in Hong Kong are 24.6 per annum per 
100,000 male and 10.4 per annum per 100,000 female (Hong Kong cancer Registry 
1997). The recognized aetiological factors for NPC include the Esptein-Barr (EB) 
virus (Cann et al. 1985)，consumption of salted and fermented fish, especially during 
childhood, and genetic predisposition (Yu et al. 1985). 
Radiotherapy (RT) is the standard therapy for curative treatment of NPC (Teo 1999). 
Patients with more advanced stage disease may also benefit from combined 
radiotherapy and chemotherapy treatment. A standard course of radiotherapy for 
NPC typically takes six to eight weeks to complete. Radiotherapy is given five 
‘days in a week, in radiation dose of 2Gy per day cumulating in a total dose of 
66Gy-86Gy (Kyle 1990; Teo 1999). An appreciable length of the upper food 
passage including the posteior oral cavity, oropharynx and part of the hypopharynx, 
and the parotid and submandibular salivary glands are commonly included within the 
radiation ports, in order to give adequate coverage of the possible sites of spread of 
the cancer. Radiation induced complications as a result of normal tissue damage, 
such as inflammation of the mucosa of the oral cavity and oropharynx, xerostomia 
V 
. d u e to salivary gland damage, and taste change, are commonly experienced by 
patients during and for some duration after the course of radiotherapy. Such 
side-effects compromise the patients' nutritional status. Reports have shown that 
weight loss is commonly seen in head and neck cancer patients undergoing 
radiotherapy and the loss can be greater than 10 % of their pre-treatment body weight 
(Chencharick & Mossman 1983; Collins et al. 1999; Lindsey et al. 1994). Evidence 
has shown that patients experience nutritional problems as a result of cancer and 
cancer treatments may further exacerbate those problems (Bassett & Dobie 1983; 
2 
Chapter 1 Introduction 
Darbinian & Coulston 1990; Donaldson & Lenon 1979). 
As NPC is uncommon in most parts of the world, the nutritional impact of 
radiotherapy treatment for this cancer has been little investigated before. This 
cancer provides a unique model of studying the impact on nutritional alteration due 
to irradiation injury to multiple sub-sites in the head and neck region, in the absence 
of disseminated cancer. In this study, the nutritional status of NPC patients before 
and after radiation therapy, and factors affecting weight change, and the long-term 
impact of weight change during radiotherapy, will be investigated. 
3 
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Malnutrition is commonly found in cancer patients, most noticeable in patients with 
cancers of the lung, head and neck, and stomach (Nixon et al. 1980). Malnutrition 
may reduce both the response to therapy and the prognosis (van Bokhorst-De van et 
al. 1999), enhances the morbidity of therapeutic side effects (Johnston et al. 1982) 
and decreases quality of life and survival (Hammerlid et al. 1998). Certain forms of 
cancer, such as lung and pancreatic cancers, are frequently associated with significant 
weight loss at the time of diagnosis (Brown & Karen 1998; Falconer et al. 1994). 
Anorexia is often associated with such weight loss, but cannot explain all of the cases 
of weight loss noted. Alteration of energy balance has been demonstrated in 
weight-losing cancer patients (Wigmore et al. 2000). The imbalance of energy may 
result from a reduced energy intake, an increase in energy expenditure, or a 
• combination of both (Falconer et al. 1994). Failure of gaining weight in 
malnourished cancer patients was noted even with adequate calorie intake, 
suggesting that these patients were hypermetabolic. Moreover, disturbance of energy 
metabolism has been noted in malnourished cancer patients, which is different from 
that under starvation. Increased whole body protein breakdown, increased lipolysis 
(Tayek 1999) and increased glucose metabolism have been demonstrated in 
malnourished cancer patients (Tayek 1992; Temell et al. 1987). Side effects of 
,anti-cancer therapy, such as chemotherapy and radiotherapy, can cause further 
deterioration in nutritional status in cancer patients (Donaldson & Lenon 1979). 
5 
Chapter 2 Literature review 
2.1 SIDE EFFECTS OF RADIATION THERAPY IN HEAD & NECK 
CACNER PATIENTS 
Radiation therapy is one of the curative treatment modalities for head and neck 
cancer patients. It can be used on its own or in combination with surgery or 
chemotherapy, depending on the exact type of cancer, the stage of the cancer and the 
medical condition of the patient.. Some of the advantages of radiotherapy include 
preservation of organ function such as the voice in treating larynx cancer, and 
avoiding the risk of surgery and anesthesia. For nasopharynx cancer, radiotherapy is 
the treatment of choice. 
A typical course of radiotherapy for head and neck cancers usually take about 6 to 8 
‘ weeks to complete. Radiotherapy to the head and neck region is associated with 
both acute and late side-effects which occur in the tissues and organs being irradiated 
(Donaldson & Lenon 1979; Kyle 1990). Inflammation of the mucosa of the upper 
food passage including that of the oral cavity, oropharynx and hypopharynx is a very 
common acute side-effect of radiotherapy to the head and neck region. 
Sore throat due to mucositis of the pharynx is one of the acute side effect that occur 
,during the course of radiation therapy. Patients may contract superimposed oral 
infections that lead to oral pain. 
Dysphagia, difficulty in swallowing, this symptom is slowly progressive throughout 
the course of radiotherapy. The difficulty in swallowing is initially noted with the 
ingestion of solid food and progresses to difficulty in swallowing liquids, including 
saliva (Grant & Rivera 1995). Study has shown that percentage of head and neck 
cancer patients experiencing dysphagia was 40% at pre-radiation and increased to 
6 
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70% at 6-week of the radiation therapy (Chencharick & Mossman 1983). Patients 
with dysphagia usually experience anorexia, dehydration, protein-calorie 
malnutrition and loss of body weight (Grant & Rivera 1995). 
Abnormality in taste may result if part or whole of the oral cavity is irradiated. 
Radiation can damage the microvilli of taste cells and their surfaces, resulting in taste 
alterations (Donaldson & Lenon 1979). Both hypogeusia, which refers to taste 
blindness, and dysgeusia may occur. With hypogeusia, patients usually complain of a 
loss of flavor and describe food as tasting flat. The latter one, dysgeusia, can create 
heightened or lowered thresholds for sweet, salty, bitter, and, to a lesser extent, sour 
taste sensations. Patients with dysgeusia often complain food tasted as rancid, bitter 
•or metallic. Chencharick and Mossman (Chencharick & Mossman 1983) had 
reported that protein-rich foods such as meats, eggs and dairy products were usually 
perceived as abnormal tasting and avoided by patients. The radiation-induced 
impairment of taste perception may occur by the second week of therapy. The degree 
of impairment and recovery varies among patients. The taste perception usually 
returns to pretreatment acuity by one year after completion of treatment or within a 
few months in some patients (Chencharick & Mossman 1983; Darbinian & Coulston 
A. 
.1990). However, permanent impairment can be seen in a small subset of patients 
(Mossman et al. 1982). 
When the salivary glands are irradiated, radiation changes the volume and quality of 
saliva. Volume of salivary secretion declines and the quality changes to viscid, acid 
mixture with abnormally high amounts of organic mineral (Donaldson & Lenon 
1979). The marked decline in salivary flow starts after the first week of treatment and 
continue to decrease throughout the radiation treatment period. At the end of the 
therapy, many patients experience severe xerostomia, dry mouth, which causes the 
7 
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chewing and swallowing problems and leads to poor oral intake (Darbinian & 
Coulston 1990). And this side effect is usually permanent. (Kyle 1990). 
The changes in the quality and decrease in the quantity of saliva and radiation 
reaction of the surrounding mucosa are general factors of developing dental caries in 
head and neck cancer patients. Decline in salivation causes an alteration in the 
composition of the oral bacterial flora that also promotes formation of caries. 
Without the effect cleansing mechanism provided by salivation, teeth would be 
covered by a tenacious material that is vulnerable to bacterial attack. Another factors 
enhancing dental caries is the lowered intra-oral pH levels. Radiation can also affect 
developing teeth by causing direct cellular damage and altering cell replication. It 
'can injure the teeth by denaturing the organic components of tooth substance. 
Symptoms of radiation dental injury are an increased sensitivity to concentrated 
sweets, heat, or cold (Darbinian & Coulston 1990; Donaldson & Lenon 1979). 
8 
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2.2 NUTRITIONAL ALTERATIONS IN CANCER PATIENTS 
Weight change is the most common outcome measure in assessing nutritional status 
of patients. Patients who have lost more then 10% of their bodyweight in the first 6 
months after diagnosis of cancer are regarded as severely malnourished, which is 
also a significant predictor for the occurrence of major postoperative complications 
(van Bokhorst-De van et al. 1998). 
Progressive weight loss in cancer patients is a common complication during the 
course of disease and treatment. For example, in a study in Isreal, unintentional 
weight loss was seen in 154 patients admitted to an internal medicine department of a 
medical center during a 2-year period (Rabinovitz et al. 1986). Retrospective analysis 
of the clinical charts indicated that more than one third (36.3%) were found to have a 
neoplasm. Another study conducted with a heterogeneous group of cancer patients 
showed that 67 % (170/254) of patients had weight loss > 5 %. This included patients 
with and without prior chemotherapy or radiotherapy (Grosvenor et al. 1989). This 
suggests that weight loss is common in cancer patients. 
Weisht loss associated with cancer itself 
,Pre-illness weight loss has been reported commonly in lung and pancreatic cancer 
patients. In one study, There were 65% of non-small-cell lung cancer patients 
encountered with weight loss of 2.5 kg or more (Brown & Karen 1998). In another 
study, almost 30 % (26/87) of non-small-cell lung cancer patients experienced more 
than 10 % of weight loss (Staal-van den Brekel et al. 1995). Falconer et al (Falconer 
et al. 1994) reported a mean percentage weight loss of 18 % in pancreatic cancer 
patients. Another study also showed a median weight loss of 12 kg compared to 
pre-illness weight in patients with pancreatic cancer (Wigmore et al. 2000). Among 
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breast, colon, lung and pancreatic cancer patients, those with pancreatic cancer had 
the highest incidence of >10% weight loss. (Dewys et al. 1980). 
Weight loss associated with cancer therapy 
Many studies have shown progressive weight loss in patients having anti-cancer 
therapy. Elderly patients with lung or breast cancer receiving radiotherapy had a 
significant decrease in mean weight by the end of treatment (Lindsey et al. 1994). 
Collins et al. shows that 49.2% of laryngeal carcinoma patients had weight loss of 
4.73 kg by the end of radiotherapy. He also demonstrated that the mean BMI of these 
patients at the end of treatment was lower than the BMI before the treatment 
(p=0.03). However, the BMI at presentation was not predictive of subsequent weight 
'loss during treatment (r=-0.35) (Collins et al. 1999). Donaldson et al. (Donaldson & 
Lenon 1979) demonstrated that 93% of head and neck cancer patients experienced 
weight loss and 9 % of them had weight loss greater than 10 %. It has been estimated 
that more than 80% of head and neck cancer patients lost a significant amount of 
weight during mulitmodal treatment (Chencharick & Mossman 1983). A mean 
overall weight loss of 2.11 kg was shown in a study with combined modality cancer 
treatment (Sloan et al. 1981). Chencharick et al, (Chencharick & Mossman 1983) 
V 
.also reported a pre-treatment weight loss of 5 kg in his group of head and neck 
cancer patients and this loss did not change during the radiotherapy. Whereas, in two 
groups of larynx and pharynx cancer patients, no significant weight loss was found 
prior to the start of radiotherapy, however, weight loss became more apparent as 
treatment progressed in the pharynx cancer group. No significant loss of lean body 
mass was found in both group but a significant loss of body fat was shown in the 
pharynx group (from 24.2% to 22.3%, p=0.02) by the end of radiotherapy 
(Macqueen & Frost 1998). 
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After the completion of treatment, weight gain was seen in lung cancer patients a 
year after surgical resection of tumors, in contrast to patients with tumor recurrence, 
who lost weight (+3.5kg vs. -3.6kg, p<0.005). Increase in weight was caused 
predominantly by an increase in fat mass (Fredrix et al. 1997). Few studies have 
reported on head and neck cancer patients' bodyweight during the rehabilitation 
period after the end of radiation therapy. Johnston et al. (Johnston et al. 1982) 
demonstrated that 68% of head and neck cancer patients undergoing radiotherapy 
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2.3 FACTORS INFLUENCING ALTERATION IN CALORIE INTAKE IN 
CANCER PATIENTS 
2.3.1 Evidence for impaired calorie intake in cancer patients 
Food intake in head and neck cancer patients had been documented in small sample 
size studies. Chencharick and co-workers (Chencharick & Mossman 1983) reviewed 
the dietary intake of five head and neck cancer patients. Calorie-deficiency was 
found when values were compared to the 1980 RDA. During therapy, the 
contribution of carbohydrates, fats and proteins to total calorie consumption changed 
with a much greater percentage of contribution of carbohydrates late in therapy, i.e. 
carbohydrate comsumption increased from 39% (172g) at early therapy to 48% 
(205g) of total calorie at late therapy. Moderate changes in energy intake and protein 
•intakes were also demonstrated in 41 patients with cancer of larynx and pharynx 
before and during radiation therapy, but did not reach a significant level (Enig et al. 
1985). 32 out of 41 patients had intake below 150% of calculated BMR, which is the 
WHO recommendation for healthy persons. A Small proportion of patients, i.e. 5-6% 
in both cancer groups, had an intake less than 0.8 protein/kg bdwt/day. The author 
explained the low energy intake during RT was probably because of both the disease 
and radiation therapy. Macqueen et al. (Macqueen & Frost 1998) also showed a 
V 
.decrease in energy intake in both larynx and pharynx cancer patients by the end of 
radiation therapy, with more drastic reduction of mean energy intake occured in 
pharynx group, i.e. from 2255kcal to 873kcal. In a small study on nutritional 
assessment of hospitalized head and neck cancer patients who received different 
treatment modalities (Westin et al. 1988)，it found that 6 out of 10 patients had 
negative energy balance, i.e. energy intake < calculated energy requirement. Among 
these 6 patients, three of them had a low percentage of proteins of total food intake, 
highest values of protein intake were recorded in patients with a positive energy 
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balance. 
Decreased in food intake is also demonstrated in other cancer patients receiving 
radiation therapy, Hulshof et al. (Hulshof et al. 19870) also showed that lowest daily 
energy intake was found in women with endometrial or cervical cancer during 
radiation therapy, the intake was soon restored to initial level (level before treatment) 
by 2 to 3 weeks after the end of radiation therapy. The study also demonstrated one 
more interesting point that, when the energy intake was the lowest, contribution of 
carbohydrates to energy intake was comparatively high which had also been shown 
in the study carried out by Chencharick et al. (Chencharick & Mossman 1983). 
Reduction in calorie intake was also shown in elderly lung and breast cancer patients 
3 months after the completion of radiation therapy (Lindsey et al. 1994)，whereas 
there was little variability from the beginning to the end of therapy. Patients could 
maintain their intake throughout the course of therapy. 
2.3.2 Anorexia 
Anorexia, defined as a loss in appetite accompanied by a decrease in food intake, is 
often seen in patients who had weight loss (Grant & Rivera 1995). Various factors 
V 
.leading to anorexia is shown in Table 2.1. 
2,3.2,1 Mucositis of upper food passage 
Changes in the upper food passage is the most prevalent factor adversely affecting 
head and neck patients' food intake. Stomatitis and oesophagitis, two of the frequent 
complications experienced by head and neck cancer patients who receive radiation 
therapy, are caused by the breakdown or ulceration of the mucosa. The changes in 
such oral mucosa may be accompanied by altered saliva production as a result of 13 
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fibrosis and the high sensitivity of the salivary glands to radiation (Darbinian & 
Coulston 1990). 
23.2.2. Change in saliva and taste，food aversions 
A marked decrease in salivary flow rate had been observed after the first week of 
radiation and became more severe during the course of treatment (Chencharick & 
Mossman 1983). The saliva becomes viscous which eventually leads to xerosotmia 
(dry mouth) and dysphagia (difficulties in swallowing). These factors lead to 
depressed food oral intake. The pain on swallowing experienced by the patients had 
also been reported to limit their diet intake (Janjan et al. 1992). Impairment of smell 
and abnormalities in taste further compromise impairment in food intake 
(Chencharick & Mossman 1983). Patients report with hypogeusia, which is a 
deterioration in taste perception, complain of a generalized loss of flavor in food; 
those report with dysgeusia, which is an altered sense of taste, often described foods 
as tasting rancid, bitter, or metallic (Darbinian & Coulston 1990; Ross 1990). 
Learned food aversions, defined as aversions to specific foods or tastes that result 
from the association of those food with unpleasant internal symptoms such as 
malaise, illness, nausea and vomiting, is common for patients to avoid many 
V 
.protein-rich and calorically dense food (Chencharick & Mossman 1983). Mattes et al 
(Mattes et al. 1992) demonstrated half of the cancer patients receiving radiation 
therapy who experienced learned food aversion had decreased appetite. 
2.3.2,3. Psychological and emotional factors 
Apart from physical factors, psychological and emotional factors are also significant 
in affecting cancer patients' appetite (Holmes 1997). Stress and depression are 
known cause of anorexia and reduced food intake (Heber & Tchekmedyian 1999; 
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Nelson et al. 1994). Other than that, previous negative perception about cancer and 
its treatment combined with fear of recurrence, the appearance of new symptoms and 
anxiety, contribute to anorexia (Schmale 1979). 
2.3,2.4 Cytokines 
Numerous cytokines, including tumor necrosis factor-a (TNF-a), interleukin 1 (IL-1) 
and interleukin 6 (IL-6) have been suggested to play a role in cancer cachexia, which 
is characterized by the induction of anorexia and loss of body weight. But little is 
known about their role in influencing weight change on cancer patients having 
radiation therapy. In animal studies, dose-dependent TNF-induced declined in food 
intake had been shown (Stovroff et al. 1988). Smith et al. (Smith & Kluger 1993) 
also found that treatment of tumor-bearing rats with TNF antiserum partially 
reversed the tumor-induced decline in food intake compared with tumor-bearing rats 
that received control serum. However, mice with methylcholanthrene-induced 
sarcomas，where anti-TNF-a monoclonal antibody delayed but did not prevent the 
development of anorexia (Elbom et al. 1993). There are conflicting reports in human 
studies also, and no study has clearly implicated it as the cause of cancer anorexia 
cachectic syndrome (CACS) (Langer et al. 2001; Nelson et al. 1994). Maltoni et al. 
V 
.(Maltoni et al. 1997) studied 61 advanced cancer patients and found that serum level 
of several cytokines, including TNF-a, IL-1 and IL-6, did not correlate with anorexia 
in them. On the contrary, Socher et al (Socher et al. 1988) did not found serum TNF 
in 19 patients who experienced cancer cachexia. Therefore, TNF may be a factor 
though not necessary the main factor accounting for cancer anorexia. 
Recent studies have demonstrated the role of neuropeptides in the regulation of 
normal appetite. Neuropeptide Y (NPY) which is a 36-amino acid peptide, is one of 
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the most abundant neurotransmitters in the brain (Kalra 1997). NPY is produced in 
the hypothalamus (Langer et al. 2001). It can produce positive energy balance by 
stimulating food intake and decreaseing energy expenditure with a reduction in 
thermogenesis in brown adipose tissue (Egawa et al. 1991), and by promoting fat 
depletion in white adipose tissue partially through decline in insulin level (Zaijevski 
et al. 1993). The NPY is able to restore normal energy balance and body fat stores 
under conditions of energy deficit by the signal of decline in leptin level. The 
simplified model is shown in Figure 2.1 and the association of NPY and leptin on 
controlling appetite is discussed in later section. 
There are studies showing that the NPY feeding system is dysfunctional in anorectic 
'tumor-bearing rats. The effect of NPY injected intrahypothalamically on the 
stimulation of food intake was less potent in rats bearing sacroma than the controls. 
Such effect was observed before the onset of anorexia and became more severe as the 
rats developed anorexia (Chance et al. 1996). Apart from this, the level or release of 
NPY was shown to be reduced in tumor-bearing rats model, whereas it was increased 
in fasting animals and in nutritional controls that had restricted food intake to match 
their body weight to the carcass weight of tumor-bearing rats (Chance et al. 1994; 
.McCarthy et al. 1993). Proposed neuropeptide activity in response to cancer cachexia 
is shown in Figure 2.2 and mentioned in later section. However, the exact nature and 
hypothalamic pathways participating in the response, especially relationships among 
newly identified peptides and cytokines, remain to be studied. 
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2.4 FACTORS INFLUENCING ENERGY EXPENDITURE IN CANCER 
PATIETNS 
2.4.1 Introduction 
Total energy expenditure (TEE) refers to the energy expended at rest (resting energy 
expenditure,REE), in physical activity (PA), and as a result of the thermal effect of 
food (TEF). These components are affected by various factors, including age, sex, 
body size and composition, genetic factors, energy intake, physiologic state, 
coexisting pathological conditions, and ambient temperature (National Research 
Council 1989). TEE in healthy subjects can be expressed in following equation: 
TEE = REE + PA + TEF 
In disease or injured patients, an additional factor, thermic effect of disease and 
injury will also become a component of determining TEE (Lee & Nieman 1996). 
When compared with healthy control groups, cancer patients have been reported to 
have decreased, normal (Knox et al. 1983) and increased energy expenditure 
(Falconer et al. 1994; Hyltander et al. 1991). Knox et al (Knox et al. 1983) measured 
REE of 200 heterogeneous group of malnourished cancer patients and found that 
26% had elevated REE, 41% had normal REE and 33% had decreased REE when 
V 
.compared with predicted values. They controlled for age, height, weight, sex, 
nutritional status, tumor burden, and presence or absence of liver metastasis and no 
correlations were found with these variables. Moreover, tumor type appears to play 
an important role in determining if an elevation of BMR is observed or not (Tisdale 
1997). Therefore, patients with pancreatic cancer were found to have elevated REE 
(adjusted for fat free mass) when compared with normal subjects. This effect was 
also more significant in patients with an acute-phase response (Falconer et al. 1994). 
Increased in REE was also reported in a study of 87 patients with lung cancer 
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(Staal-van den Brekel et al. 1995) and REE adjusted for fat free mass in them was 
also increased (Fredrix et al. 1991; Staal-van den Brekel et al. 1997)，whereas 
generally no increase was noted for patients with gastric or colorectal cancer (Fredrix 
et al. 1991). For cancer patients who received treatment, Luketich et al. (Luketich et 
al. 1990) reported a decline in BMR in hypermetabolic patients who had tumor 
resection. In a study of energy balance in non small cell lung cancer patients, 
elevation of REE was demonstrated before tumor resection but decreased to a normal 
level within 3 month after curative surgery. This observation had explained for a 
weight gain of approximately 1 kg in 3 months (Fredrix et al. 1997). Jebb et al. had 
reported increased energy expenditure in small cell lung cancer patients. For those 
who responded to chemotherapy, there was a significant decrease in REE and even 
normalization in most of them; however, there was no increase in their bodyweight, 
probably because of the side effects of chemotherapy. In the non-responders to 
systemic antineoplastic treatment, there was no change in REE, which proved that an 
increase in energy expenditure in basal conditions indeed constituted a true 
paraneoplastic syndrome. There was a further weight loss induced by chemotherapy 
and its side effects in these patients (Jebb et al. 1994). There were little literature 
concerning energy expenditure in head and neck cancer patients and those responded 
to radiation therapy. Shaw and co-workers (Shaw et al. 1988) had demonstrated the 
REE in a small group of weight losing patients, who consisted of both head and neck 
cancer and non-cancer patients. No elevated REE was found in both groups of 
patients. Another small group of larynx and pharyngeal cancer patients was studied. 
The measured BMR decreased in both subgroups during radiation therapy, but this 
was only to a significant level in pharynx group with more degree of weight loss 
(Macqueen & Frost 1998). 
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From previous findings, although primary tumor site is important, it is not possible to 
estimated REE in patients with cancer based on tumor site of stage of disease with 
current formulae. The tumor-host interaction is complicated in its effects on REE 
(Knox et al. 1983). 
Weston et al. (Weston et al. 1989) showed that DIT, either expressed in terms of 
metabolic body size or lean body mass, was significantly reduced in the 
weight-losing cancer patients compared with weight-stable cancer patients and 
control patients after a test meal which provided a third of the recommended daily 
amounts of food (14% from protein, 38% from fat and 46% from carbohydrate). A 
study in elderly cancer patients without report of losing weight reported that the 
glucose-induced thermogenesis (GIT) was lower in cancer patients when compared 
with age and percent body fat matched control. It also suggested that plasma TNF-a 
level might play a major role in the alteration of GIT (Gambardella et al. 1997). 
Energy metabolism 
Changes in energy expenditure in cancer patients have been well documented. 
Alterations in substrate utilization with excessive mobilization of lipid, alteration in 
V 
.glucose metabolism and reduction in the efficiency of energy metabolism have been 
demonstrated (Gambardella et al. 1997; Young 1977). Those various abnormal 
metabolic pathways may be responsible for the change in energy expenditure in 
cancer patients (Knox et al. 1983). 
1) Glucose metabolism 
In study of tumor bearing animal models indicated that tumor might rely on 
anaerobic glucose metabolism, with most being converted to lactate (Nolop et al. 
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1987). Compared with oxidative phosphorylation, glycolysis is an inefficient method 
by which to generate energy from glucose. High levels of glucose will be consumed 
by the tumor. In colon tumor bearing mice, glucose utilization by the tumor was 
second only to that by the brain in host (Mulligan & Tisdale 1991). The extra 
demand for glucose by the tumor was accompanied by a marked reduction in glucose 
utilized by the host (Tayek 1992). 
Increase in Cori cycle activity has been noted in the tumor bearing animal models 
and in some patients with cancer, as both hepatic glucose production and glucose 
recycling are significantly increased. Cancer patients had showed a 40% increase in 
hepatic glucose production compared with control subjects (Tayek 1992). Glucose 
production rates and recycling rates were found to be higher in malnourished cancer 
patients than in patients without cancer and with comparable weight loss (Eden et al. 
1984). The Cori cycle involves the metabolism of glucose to lactate by tumor cells 
and the conversion of the lactate to glucose in the liver. The conversion of lactate to 
glucose is a net loss of adenosine triphosphate (ATP) and appears to be an 
energy-wasting biochemical process that may contribute to the tissue wasting and 
weight loss seen in cancer patients (Holroyde & Reichard 1981; Langer et al. 2001; 
’ .Rivadeneira et al. 1998). 
2) Fat metabolism 
Wasting process involves the mobilization of fat from depots in the body. In normal 
fasting subjects, this process is increased. For cancer patients, various reports have 
also shown extensive abnormalities in fat metabolism with increased glycerol and 
fatty acid turnover. These abnormalities contribute to the excessive loss of fat mass 
relative to lean body mass (Kem & Norton 1988; Kokal et al. 1983; Tayek 1999)， 
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which is a feature of cancer cachexia. 
Under normal conditions, high glucose concentration should suppress lipolysis, but 
this effect is reduced in weight-losing cancer patients (Shaw & Wolfe 1987)，that 
fatty acids are still preferentially used as an energy source (Gambardella et al. 1997; 
Mc Andrew 1986). Moreover, weight losing cancer patients are usually 
hyperlipidemic (Spiegel et al. 1982). The hyperlipidemia has been related to 
decreased lipoprotein lipase activity, which is possibly modulated by the cytokine 
TNF-a (Marshall et al. 1994). The increased fatty acid oxidation in the absence of 
increased dietary fat intake would result in body fat deposition, while increased 
triglyceride fatty acid cycling and gluconeogenesis from glycerol could lead to an 
increase in metabolic rate. Therefore, such processes have the potential to contribute 
to a net loss of body weight (Tisdale 1997). 
3) Protein metabolism 
Depletion of lean body mass and visceral protein are characteristics of cancer 
patients who lose weight, and the degree of depletion may be associated with 
reduced survival (McMillan et al.' 1994; Nixon et al. 1980). Decrease rate of muscle 
V 
protein synthesis (Emery et al. 1984; Lundholm et al. 1976) and increase rate of 
muscle protein degradation had been shown in weight-losing cancer (Lundholm et al. 
1976)，which skeletal muscle representing the major site of protein loss. Such 
inappropriate protein breakdown provides substrate for gluconeogenesis, which 
cannot be fully suppressed even with glucose infusion (Nixon et al. 1980). The 
introduction of total parenteral nutrition (TPN) had been failed to suppress the 
protein turnover rate (Norton et al. 1981). 
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Apart from the abnormalities in protein degradation, a decrease in muscle protein 
synthesis was apparent in weight-losing cancer patients. The percentage of muscle 
protein synthesis in total body synthesis in them was much lower than that in healthy 
control subjects (8% vs. 53%). It means there is an increase in nonskeletal muscle 
synthesis in cancer patients, which may due to an increase hepatic synthesis of 
secretory proteins, such as acute phase reactants (Emery et al. 1984)，which is a 
product of acute phase response, a basic defensive response of the body against 
injury (Tayek 1999). 
Elevation of whole body protein turnover was seen in both weight-losing and weight 
stable lung and colorectal cancer patients. Although the rate in cancer patients was 
t 
50-70% greater than controls, this did not result in a significant increase in resting 
energy expenditure (REE). The REE did not correlate with increase in protein 
turnover rate, and the presence of acute phase protein response (Fearon et al. 1988). 
2.4.2 Components of total energy expenditure 
2.4.2,1 Measurement of Basal metabolic rate 
BMR or REE accounts for 65-75% of TEE, measurement of BMR or REE is a 
V 
.general practice in reflecting energy expenditure of cancer patients in clinical setting 
(Lee & Nieman 1996). 
In order to compare energy expenditure between individuals, normalization of data 
must be done, which corrects for the primary confounding variables of height, weight 
(Knox et al. 1983) and body composition (Nielsen et al. 2000; Rising 1995). 
Common normalizing factors are body weight and fat free mass (FFM). In obese 
subjects, surface are should also be considered (Delany & Lovejoy 1996). These 
22 
Chapter 2 Literature review 
factors are proportional to BMR with FFM is more preferable than body weight as it 
consists of the metabolically active tissue in the body. Moreover, FFM often gives 
slightly higher correlation. The reason for surface area as normalizing factor is 
because heat is lost through the skin .BMR should be proportional to the amount of 
skin (Delany & Lovejoy 1996). 
As defined in Recommended Daily Allowances (National Research Council 1989), 
“Resting energy expenditure (REE) represents the energy expended by a person at 
rest under conditions of thermal neutrality". BMR is more precisely defined as the 
REE measured soon after awakening in the morning, at least 12 hours after the last 
meal. However, REE is not always measured under basal conditions, which may 
include the residual thermic effect of a previous meal and may be lower than BMR 
during quiet sleep. In practice, the terms, BMR and REE, are used interchangeably 
for they usually in difference by no more than 10 %. 
Determinants of resting energy expenditure 
The major determinants of REE are age, sex, height, and weight (Knox et al. 1983). 
(i) Age ‘ 
V 
REE changes with the amount and composition of metabolically active tissue, which 
changes with age. The lean body mass of infants and children contains a greater 
proportion of metabolically active organs than that in adults. A steady decrease is 
seen between birth and sexual maturity, and reaching a more constant level by the 
age of 20. In adults, skeletal muscle, a less metabolic active tissue, is a main 
component of the lean body mass. Throughout the remainder of the life span, there 
will be a more gradual decrease in metabolic rate at a rate of 1-2% per decade (Knox 
et al. 1983). However, in a study of 200 heterogeneous hospitalized cancer patients 
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with age range of 33 to 87 years, Knox et al. found that the hypometabolic subjects 
were significantly younger (52.2 vs. 63.7 years) than hypermetabolic subjects. The 
highest REE was observed in the oldest subject. An opposite result of the age effect 
in normal subjects is shown. Therefore, the differences in REE in these cancer 
patients are not due to age effect. 
(ii)Sex 
Sex affects metabolic rate in female with a slightly lower value than males. This can 
reflect the differences in body composition with men having a greater proportion of 
lean body mass than women. The differences in body composition between sexes are 
small during childhood. The differences become greater after maturity. In adults, 
REE per kg of body weight differs by approximately 10 % between sexes. However, 
the REE corrected for per kg body weight and FFM (fat free mass) was not 
significantly different in both colon and lung cancer patients between sexes (Nixon et 
al. 1988). Same results are shown in esophageal cancer patients (Thomson et al. 
1990). 
Those results discount a sex effect in the measured REE in cancer patients. 
V (iii) Body size 
Body size is the most important determinant of energy expenditure. People with large 
bodies require proportionately more energy per unit of time for activities (e.g. 
walking). Their total REE will be higher than the average for people of the same sex 
and age (National Research Council 1989). 
REE represents the energy necessary for all metabolic activity of oxygen consuming 
tissues necessary for maintenance of life. Therefore, REE is directed related and 
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proportional to lean body mass, whereas fat mass consists mainly of triglyceride 
which has little or no metabolic activity. Thus, in healthy subjects, the heavier the 
subject, the higher the BMR (Linder 1991; Tayek 1999). However, according to the 
result demonstrated by Knox et al (Knox et al. 1983), the hypermetabolic group 
subjects weighted significantly less than hypometabolic and normometabolic 
subjects, with the hypermetabolic group had a smaller metabolic body size also. 
Again, this is directly opposite to the observations in normal subjects. 
Additional factors influencing REE are illness/injury, and major surgery (Knox et al. 
； 
1983; Linder 1991). The REE in cancer patients and those receiving surgery, 
chemotherapy and radiotherapy have been reviewed in previous section. Some 
inflammatory factors, i.e. cytokines and tumor neocrosis factor (TNF), are also 
proposed to affect REE, which will be discussed in later section. 
2.4,2.2 Energy cost of physical activity 
Activity-induced energy expenditure is the second largest component contributing to 
TEE. It accounts for 15-20 % of TEE. The energy expenditure in physical activity is 
traditionally calculated from the duration on various work and leisure activities and 
V 
assigning energy cost to each of them. This energy cost can be expressed as a 
multiple of BMR, eg. 1.2 * BMR for sitting with no other physical activity taking 
place, 1.7 * BMR for standing activities at work etc (Department of Health 1991). Or 
in other words, the physical activity can be described through three dimension, which 
are duration (e.g., minutes, hours), frequency (e.g. times per week or per month), and 
intensity (e.g., rate of energy expenditure in kcal per min. or kJ per hour) (Montoye 
et al. 1996). An expert consultation by FAO/WHO/UNU (WHO (World Health 
Organisation) 1995) estimated the PAI (physical-activity index) based on observed 
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patterns of activity and the laboratory determinations of the associated energy costs 
of the observed activities. The PAI was calculated for three categories: 1.5 for 
light-activity work (office clerk), 1.8 for moderate-activity work, and 2.1 for heavy 
work. With known activity pattern, ones energy requirement can be determined: 
Energy requirement = BMR * Activity Factor 
For those with disease/bum/after operation, an additional injury factor is multiplied 
to the above equation. The injury factor for cancer cachexia ranges from 1.3 to 1.5 
(Long et al. 1979). 
2,4.2.3 Thermic effect of food (TEF) 
Another component of TEE is the thermic effect of food, also known as diet- induced 
thermogenesis (DIT) or the specific dynamic action of food, which is the increased 
energy expenditure following food consumption or administration of parenteral of 
enteral nutrition. This is the energy cost of nutrient absorption, transport, storage and 
metabolism. It accounts for about 7-10% of TEE (Lee & Nieman 1996). Fat is the 
least "expensive" in terms of DIT, which require relatively little hydrolysis and a 
fairly direct pathway to storage tissue. Carbohydrate is intermediate. Protein is the 
most “ expensive" overall for DIT requiring expenditure of up to 30 % of the 
V inherent energy for processing (Under 1991). 
26 
Chapter 2 Literature review 
2.5 METHODS FOR NUTRITIONAL ASSESSMENT 
2.5.1 Body weight and body composition 
There are several direct and indirect techniques used to determine body composition, 
including anthropometric measurements, bioelectrical impedance analysis, 
dual -energy-X-ray absorptiometry, total body water and total body potassium. These 
methods will be discussed in the following. 
1) Anthropometric measurements: anthropometric measurements include height, 
weight, body mass index, skinfold thickness, and arm circumferences (Pichard & 
Kyle 1998). Body weight is suitable in long-term follow-up in terms of 
quantifying body mass (body fluid and tissue mass). A body weight loss of <5% 
« 
is generally regarded as not signficiant while a 5-10% loss is potentially 
significant. A weight loss >10% is definitely significant (Lee & Nieman 1996). 
However, body weight does not show information on body compartments and is 
not valid in individuals with hydration problems. Skinfold thickness measures the 
subcutaneous fat mass at different sites on the body and these data is used to 
estimate body fat mass by validated prediction equations. Arm circumference is 
used to estimate lean and muscle mass. However, these methods have limited 
V 
• accuracy and cannot determine the proportions of fat free mass (FFM) and fat 
mass. Also, it is not appropriate for assessing small changes in lean or fat tissue 
in critically ill hospitalized patients (Jensen 1992). 
2) Bioelectrical impedance analysis (BIA): BIA bases on the assumption that body 
composition composed of fat mass (FM) and fat-free mass (FFM). The FM refers 
to body fat，whereas the FFM refers to two main components: body water, and 
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protein, mineral and electrolytes. It measures the body's resistance to a harmless 
current running through the body (Lee & Nieman 1996; Pichard & Kyle 1998). 
The resistance and reactance are then used to determine fat-free mass or total 
body water by standardized prediction equations with other variables, such as 
height, weight and sex (Pichard & Kyle 1998). It has been used to measure body 
composition in healthy (de Lorenzo et al. 1998) cancer (Fredrix et al. 1990) and 
HIV (Mulligan & Bloch 1998) subjects. This measurement is easy to perform and 
noninvasive. However, the weakness is it assumes the subjects are normally 
hydrated. Therefore, dehydration can result in overestimation of FM (Lee & 
Nieman 1996). 
3) Dual -energy-X-ray absorptiometry (DEXA): DEXA is a scanning technique to 
measure bone mass, bone density and body composition (Tolli et al. 1998). 
Patient is scanned with photons generated by X-ray at two different energy levels 
and the differential absorption of the photons is measured. The ratio of 
absorbance of the two different energy level photons is linearly related to the 
percentage of fat in the soft tissues of the body. With this ratio, the total body fat 
and fat-free mass can be determined accurately (Jensen 1992). The compartment 
V 
. o f body composition measured by DEXA consists of fat mass (body fat), lean 
mass (body protein, electrolytes and water), and bone mass (mineral). It can 
determine the fat mass directly rather then by subtracting the other body 
compartments. Also, it can give the distribution of fat and lean mass between 
trunk and four limbs. The coefficient of variation of fat-free tissue measurement 
is approximately 2 % (Jensen 1992). However, it does not measure total body 
water .An assumption of 73.2% of fat-free mass for TBW is made instead 
(Pichard & Kyle 1998). This can results in overestimation of protein mass in 
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underhydrated subjects. DEXA is a simple, safe and precise technique that can 
measure bone mineral and soft tissue composition in the whole body and specific 
regions (Pichard & Kyle 1998). Moreover, DEXA and BIA could be performed 
as complimentary methods to assess body composition in chronic disease: 
evaluate patients at baseline by both BIA and DEXA and then by BIA during 
follow-up (Pichard & Kyle 1998). 
4) Total body water (TBW): As fat is free of water, all the water in the body is found 
in the fat-free mass. It is assumed that the fat-free mass has a water content o 
approximately 73.2%. Therefore a measure of TBW can calculated total body fat 
with specific formula. The TBW is estimated by giving a known concentration 
‘ a n d volume of oral or intravenous dose of isotopic tracer. Tritium and deuterium 
are two commonly used tracers (Lee & Nieman 1996). After an equilibration 
period, the tracer is then measured in a sample of body fluids, either urine, blood 
or saliva, by gas chromatography, infra-red absorption or mass spectrometry 
(Jebb & Elia 1993). However, this is not suitable with obese subjects and subjects 
with fluid abnormalities (Pichard & Kyle 1998). This method has been shown to 
overestimate metabolically active tissue in weight-losing cancer patients 
V 
. (McMil lan et al.). This method has been limited for clinical research use because 
of its high cost, complex laboratory techniques and exposure to radiation (Pichard 
& Kyle 1998). 
5) Total body potassium (TBK): As 90% of all the body's potassium is located 
within fat-free tissues, and 0.12% of all potassium is the naturally occurring 
potassium-40 isotopes，which emits very small detectable amount of gamma 
radiation (Lee & Nieman 1996) detected by spectrum analyzer. Therefore, this 
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method based on the assumption that fat-free tissue has known and constant 
potassium content. The measured TBK content represents the body cell mass 
from which the FFM can be extrapolated. However, this method cannot be 
performed in critically ill patients and those with significant change of body 
water (Pichard & Kyle 1998). 
Choice of method for measuring body weight and composition for present study 
In order to select the appropriate method for assessment, the objective of study, 
availability of resources and extent of discomfort to the patients, have been 
considered. One of the objectives of the study aims at assessing the change in fat 
mass and lean mass of NPC patients during the course of study. Therefore, 
Dual -energy-X-ray absorptiometry (DEXA) was used. This method has been 
advocated to measure body composition in hospitalized cancer patient, as it does not 
depend on total body water content to calculate fat free mass (lean and bone mass) 
and fat mass (Rising 1995). It determines the fat mass without making assumptions 
related to lean mass, potassium concentration or density, which is the basic of TBK 
and TBW methods (Pichard & Kyle 1998). In addition, the measurement time for 
whole body scan is short which can minimize patient's discomfort. Also, the analysis 
V 
and report are quick to generated. 
2.5.2 Dietary intake 
Measurement of diet intake usually is for one of the three purposes: to estimate an 
individual 's usual daily intake, to compare average nutrient intakes of different 
groups and to rank individuals within a group. There are a number of diet measuring 
methods, which can be categorized as daily food consumption methods (24-hour 30 
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recall and food record) and average (or "usual") food consumption methods (dietary 
history and food frequency questionnaire). These techniques have also been 
alternatively categorized as meal-based (24-hour recall and food record) and 
list-based (food frequency questionnaire). Several common methods for measuring 
individual dietary intake are listed as follows (Lee & Nieman 1996): 
1) 24-Hour Recall', the interviewer asks the respondent to recall in detail all the food 
and drink consumed during a period of time in the recent past, usually for the 
previous 24 hours. The interviewer then records the information for later coding and 
analysis. During the time for recording response, interviewers helps the respondent 
recalling all the food consumed in questions and assists the respondent estimating 
portion size. 
Some researchers may also ask the respondent about his/her activities performed 
during the 24-hour period, which may be associated with eating or drinking. This can 
help in recalling food intake. The recall can be done by face-to-face or telephone 
interview. The record can then be analyzed by a computerized program. This method 
is inexpensive, easy to administrate, required no more than 20 min and can provide 
detailed information on types of food consumed. The limitations are that recall is 
seldom representative of a respondent's usual intake, under or over reporting may 
occur and it greatly relies on memory. 
2) Food Record/Diary', at the time of consumption of food, the respondent records 
the items and quantities of all foods and drinks consumed for a period of time, which 
usually ranges from 1 to 7 days. The portion sizes are quantified by household 
utensils, i.e. cups, tablespoon, teaspoon and bowl. This refers to "estimated food 
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record". When food is weighed for recording quantity, it is referred to as "weighed 
food record". The advantages are that it is does not rely on memory, can provide 
detailed intake data and eating habits. However, it requires high degree of 
cooperation. The respondent must be literate and sometimes, the recording procedure 
may change the diet. 
3) Food Frequency Questionnaire', the questionnaire assesses energy and/or nutrient 
intake by finding how frequent a respondent consumes a limited number of food 
items. Food lists can include as many as 100 items or fewer. Usually respondents tell 
how many times a day, week, month or year that they consume the foods (Block 
1989). This is called “ simple food frequency questionnaire". If an idea of portion 
sizes are given to the respondent, it is called “ semiquantitative food frequency 
questionnaire". In “ quantitative food frequency questionnaire", the respondent is 
told to describe the usual serving as small, medium, or large relative to a standard 
serving. These questionnaires can be done by telephone interview or 
self-administrated in face-to-face interview. The strengths of the questionnaires are 
that they are more representative of usual intake than a few days' diet records and are 
suitable for large-scale studies. The limitations are that they may not represent usual 
V 
portion sizes chosen by respondent and depend on the ability of respondent to 
describe diet. Also the intake data may be compromised when multiple food items 
are categorized within single listings. 
4) Diet History: this is for assessing a respondent's usual dietary intake over an 
extended period of time, i.e. over months，years (van Staveren et al. 1985; Vinken et 
al. 1999). This is firstly done by collecting general information on the respondent's 
health habits, conducting a 24-hour recall, cross-checking on the data on 24-hour 
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recall, and conducting a 3-day food record. This last step is sometimes omitted by 
some researches. The advantages are that it can detect seasonal changes of dietary 
intake and assesses usual nutrient intake. However, the drawbacks are that it required 
a long time to complete and it is difficult and expensive to code food items. 
5) Duplicate Food Collections: in this method, participants have to place in 
collection containers and identical portion of all foods and drinks consumed during a 
specified period. These foods and drinks are then chemically analyzed at a laboratory 
for nutrient content (Kim et al. 1984). The advantage is that it can provide more 
accurate data on the nutrient intake then the calculations based on food composition 
tables. The limitations are that more time and effort is needed to collect duplicate 
samples, and it may underestimate usual intake. 
V 
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Choice of method for measuring dietary intake for present study 
When choosing appropriate method, one has to consider the objective of study, 
availability of manpower and resources. In order to estimate current food intake at 
« 
different time points for NPC patients, 3-day food record was used in present study. 
This method does not depend on patient's memory. Also, it can provide detailed 
current dietary intake data. The portion size estimated during or just after meal can 
be more accurate. 3-day record can be more representative of patient's usual intake. 
1-day food record instead of 3-day record was used when measuring diet during the 
course of radiation therapy. It aimed at lowering patients burden during treatment, 
and usually, food consumed by the patient and eating habit did not vary much during 
tHe course of radiation therapy. Moreover, 24-hour recall was used as an alternative 
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2.6 METHODS FOR ENERGY EXPENDITURE MEASUREMENT 
There are several different methods for directly measuring or indirectly estimating 
24-hour energy expenditure. These include direct/indirect calorimetry, double labeled 
water, questionnaire and heart rate. Each of them has its advantages and 
disadvantages. Selection of a method to assess 24-hour energy expenditure depends 
on the resources available, the research questions being asked and minimization of 
discomfort to the patients (Schoeller & Racette 1990). 
1) Direct Calorimetry. it requires a special designed chamber or suit in order to 
measure both in sensible heat given off by human body and the latent heat of 
vaporized water from the lungs and skin. The subject is required to be confined 
‘within the sealed chamber or suit for at least 24 hours. Although this method 
gives good accuracy, it is not suitable for critically ill patients. The measurement 
cannot be done for less than 24 hours, which can give much discomfort to the 
patients. Also, it cannot give relative contribution of different substrates to 
energy expenditure (Lee & Nieman 1996; Murgatroyd et al. 1993). 
2) Indirect Calorimetry. This method measures gas exchange, i.e. whole body 
V 
. o x y g e n uptake (VO2) and carbon dioxide release (VCO2). With known volume of 
expired air, and the differences in oxygen and carbon dioxide concentrations in 
inspired and expired air by the body, the body energy expenditure can be 
calculated. It is based on the assumptions that 1) all the O2 uptake is used in 
oxidative metabolism; 2) all the CO2 expired is derived from the complete 
oxidation of fuels; and 3) all the nitrogen resulting from protein oxidation is 
collected and measured accurately (Lee & Nieman 1996; Reid & Carlson 1998). 
Indirect calorimetry can be used either in the closed circuit or open circuit mode. 
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In closed circuit calorimetry, the subject is connected via a mouthpiece or mask 
to a spirometer filled with a known amount of 100% oxygen. The subject 
rebreathes only the gas within the spirometer. Expired CO2, which is removed by 
a canister of soda lime, and consumed oxygen within the spirometer is then 
measured. In open circuit calorimetry, the subject breathes via a two-way valve in 
which room air is inspired from one side of the valve, and expired air passes 
through the opposite side to where it is analyzed. The common approach in open 
circuit calorimetry is the use of ventilated hood indirect calorimeter. Expired air 
is removed from the hood enclosing the subject's head. At the same moment, a 
constant flow of air is supplied into the hood for the subject to inspire. It can 
determine .the O2 and CO2 content of both inspired and expired air. Energy 
‘expenditure and substrate utilization can also be determined. The accuracy and 
precision are 1 % and 2-3 % respectively (Schoeller & Racette 1990). The use of 
a hood can give less discomfort than the use of a mouthpiece of facemask, and 
give more accurate and representative results of metabolic rate in the critically ill 
patients (Reid & Carlson 1998; Shaw & Wolfe 1987). 
3) Doubly Labeled Water (DLW): in this method, patient drinks known amount of 
. w a t e r doubly labeled with deuterium (^H) and oxygen 18 (^^O). Then, the 
patient's body's elimination of the doubly labeled water is measured periodically 
through urine and blood samples over the next 1 to 3 weeks. This approach is 
based on the assumption that ingested DLW is distributed rapidly and 
homogeneously within the body water pool, and oxygen atoms in exhaled carbon 
dioxide and water are in isotopic equilibrium. ^^ O will label both the water and 
2 . 
carbon dioxide pool, whereas H will label the water pool only. Therefore, the 
difference between the elimination rates of ^^ O and ^H is an index of VCO2, 
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which is proportional to TEE. DLW method has an accuracy of 1 % and a 
coefficient of variation of 3-6 % (Lee & Nieman 1996; Montoye et al. 1996). It 
appears to be the best method of monitoring the energy expenditure of free-living 
subjects. As the measurement is conducted over a period of time, the EE found is 
representative. However, the high cost of isotopes and analyzing the samples 
limits its use to small group studies. Moreover, it gives the TEE over a period of 
time but cannot give information on different activity patterns (Montoye et al. 
1996). 
4) Activity Survey. It is usually peformed in the form of questionnaires and daily 
activity diaries. The reported data are often converted to estimation of energy 
‘expenditure based on values of different activities obtained from published tables 
(Caspersen et al. 1991; McArdle et al. 1991) and is able to tell the subject's 
activity pattern. The questionnaire can be completed either by the subject or with 
an interviewer (Schoeller & Racette 1990). It often includes a number of 
occupational and leisure activity items with different energy costs (Washburn & 
Montoye 1986). Estimation of TEE per day is based on the definition of the 
energy cost. The subject needs to recall the type, frequency and duration of 
V 
. ac t iv i t ies performed. There are a number of questionnaires being published, i.e. 
Tecumseh Survey, Seven-day recall and Baecka (Melanson & Freedson 1996). 
While diary method requires the subject to record each activity throughout the 
day which can be more informative, a 7-day activity recall can be used in 
conjunction with activity diaries to enhance accuracy (Schoeller & Racette 1990). 
However, diaries require subject cooperation and motivation, and may alter 
normal activity pattern (Melanson & Freedson 1996). 
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5) Mechanical or Electrical Monitors'. Activity and heart-rate monitors are 
alternative approaches that can estimate energy expenditure. Activity monitors 
measure the movement of trunk or limbs. Portable devices worn on the wrist or 
belt, i.e. accelerometers，assess energy expenditure by sensing accelerations of 
the body during physical activity. Regression equations applied to the data allow 
calculation of oxygen consumption and EE. However, their use is limited to 
dynamic activities. Static activities cannot be assessed accurately. Heart-rate 
monitors used to assess EE based on the direct association between heart rate and 
oxygen consumption during physical activities. However, their precision for 
assessment of EE is limited by the fact that heart rates can change independently 
of physical activity. Emotions, fatigue, body temperature and hydration state can 
‘ a f f ec t heart rate without relative change in oxygen consumption (Schoeller & 
Racette 1990). 
6) BMR multiplied by physical activity factor (PAL): the average EE can be 
estimated from measured or estimated BMR, multiplied by an appropriate 
activity factor which depends on the degree and duration of physical activity, i.e. 
BMR X PAL. The PAL may vary from 1.2 to 1.4 for inactive subject and up to 
V 
. 2 . 0 or above for very active one. The factor by which BMR must be multiplied 
may be determined from timed activity record, questionnaire designed to provide 
information on habitual physical activity. For disease or injured subjects, an 
additional injury factors will be multiplied, varies from 1.0 to 1.3 for surgery and 
up to 1.8 or above for serious trauma and bum (Dumin 1996; Lee & Nieman 
1996)，whereas that for cancer cachexia is 1.3 to 1.5 (Long et al. 1979). This 
approach greatly depends on sufficient information on subject's lifestyle. The use 
of activity factor is usually served as an index of EE in groups or population and 
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not to individual (Dumin 1996). 
Choice of method for measuring energy expenditure for present study 
It is difficult to estimate, using standard equations, the energy demands of the 
critically ill patients. Without actual measurement of metabolic demands it is 
impossible to precisely determine nutritional status of patients as the energy 
expenditure vary considerably (Reid & Carlson 1998; Rising 1995). Among the 
above approaches, indirect calorimetry with ventilated hood was used for measuring 
BMR in patients. This method was chosen firstly because it had been widely used in 
assessing cancer patients' energy expenditure (Falconer et al. 1994; Fredrix et al. 
1997; Macqueen & Frost 1998; Staal-van den Brekel et al. 1995), secondly because it 
is easy to operate, thirdly because it is associated with less discomfort to patients. For 
determination of patients' TEE, the physical activity questionnaire was used, in 
consideration of its low cost, ease of administration, and ability to give information 
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2.7 CYTOKINES AND LEPTIN CHANGES IN CANCER PATIENTS 
2.7.1 Cytokines 
Cytokines are protein synthesized and released by blood monocytes and tissue 
macrophages in response to inflammatory stimuli and exert diverse biological effects 
even at low concentration (Fong et al. 1989a). They serves as hormones, stimulating 
responses in nearby or distant cells and tissues (Beisel 1991). Among various 
cytokines, tumor necrosis factor (TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6) 
have reached much concern in recent cancer research studies, suggesting that those 
proinflammatory cytokines act as mediators of metabolic change. 
2.7丄1 Tumor necrosis factor 
Oh the study of cachexia in chronic infection, Beutler and Cerami (Beutler & Cerami 
1988; Oliff 1988) reported that rabbits infected with trypanosomes lost weight and 
had hypertriglyceridemia. They discovered this was because of an inhibition of 
lipoprotein lipase (LPL). In the serum of animals treated with lipopolysaccharide, it 
contained the same inhibitor of LPL, suggesting that it resulted from immune 
activation. In the view of this potential role in wasting, it was called “ cachectin". 
In earlier studies done by Norton et al (Norton et al. 1985), he found that the serum 
V 
of mice treated with endotoxin had antitumor activity. This factor was isolated from 
macrophages and called “ tumor necrosis factor" (TNF). Moreover, immunologic 
studies and reciprocal measurements of bioactivity indicated that cachectin and TNF 
were identical molecules (Beutler & Cerami 1988). 
TNF is a cytokine released from activated macrophages and monocytes, and natural 
killer cells. Its release is stimulated by injury, bacterial endotoxin, inflammatory 
agents, i.e. IL-1 and IFN. 
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Correlation of TNF with lipolysis has been shown in many studies (Elbom et al. 
1993; Orban et al. 1999)，the close correlation with lipolysis suggests its role in 
participation of a local positive autocrine feedback loop potentiating lipolysis and 
inhibiting insulin's antilipolytic activities. The TNF inhibits production of lipoprotein 
lipase which inhibits the formation of new fat, whereas enhancing lipolysis by 
activating hormone-sensitive lipase. 
TNF has also been shown in several studies (Costelli et al. 1993; Llovera et al. 1993) 
to activate muscle protein degradation. However, not all of the studies agree that 
TNF does activate protein degradation directly. Llovera et al (Llovera et al. 1993) 
TNF-a administration to healthy rats brought about an enhanced rate of degradation 
of skeletal muscle protein, even though body weight loss was not apparent in the 
animals. In another study (Costelli et al. 1993), administration of anti-murine TNF-a 
immunoglobulin to rats bearing the Yoshida AH-130 ascites hepatoma led to decline 
in the rates of muscle, heart and liver protein degradation, but had no weight loss in 
them. However, a direct action of TNF on proteolysis has not been shown by most 
other studies (Moldawer et al. 1987c). Moldawer et al demonstrated that although 
V 
IL-1 and TNF-a induced prostglandin E2 response by skeletal muscle in vitro, some 
macrophage product distinct from either IL-1 or TNF-a was responsible for 
accelerated muscle degradation seen with partially purified human blood monocyte 
products. 
The effect of TNF is also believed to contribute to fat depletion and cachexia in 
chronic illness. Chronic exposure to low levels of cachectin leads to anorexia and 
wasting, which can last for months. This state resembles cachexia as it is observed in 
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association with invasive neoplastic diseases and various infectious disorders 
(Beutler & Cerami 1988). Those effects have been shown in animal and human 
studies. Tumor transfected with the gene for human TNF and implanted with or 
without the transfection led to continuous production of TNF. The TNF-secreting 
tumor bearing mice showed progressive anorexia, weight loss, fat depletion, and 
earlier death compared to the animals bearing the nonsecreting tumor (Oliff et al. 
1987). The acute administration of TNF or short intravenous infusion of recombinant 
human TNF-a in humans also led to and elevation in acute phase protein synthesis 
from hepatocytes, increase of resting energy expenditure, promotion of lipolysis and 
proteolysis, and anorexia (Falconer et al. 1994; Selby et al. 1987; Stames et al. 1988; 
Stovroff et al. 1988; Toomey et al. 1995), features that are all demonstrated in 
patients with cancer wasting. However, several studies could not detect increased 
circulating levels of TNF-a in cachectic cancer patients (Socher et al. 1988)，or 
failed to associated the elevation with the development of cachexia (Balkwill et al. 
1987). Many authors suggested that elevation of serum TNF-a seems to be 
associated more with the clinical status of the patient (Langer et al. 2001; Tisdale 
1997). This has been supported by the study showing that serum levels of TNF-a 
were elevated in all stages of patients with B-cell chronic lymphocytic leukemia with 
V a.progressive increase in relation to the stage (Adami et al. 1994). 
Although the detection of TNF level partially depends on the technique applied and 
the sensitivity of the experimental kit. It has been suggested that the inability to 
correlate serum levels of TNF-a with the development of cancer cachexia may be 
due to the very rapid blood transit of cytokines. Therefore，they can be transported 
from the sites of production to the target tissues with out causing an elevated serum 
concentration (Tisdale 1997). 
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Apart from lipolysis and proteolysis, the effect of TNF on energy expenditure has 
been reported (Staal-van den Brekel et al. 1995; Stames et al. 1988; Tracey et al. 
1989). Tracey et al. (Tracey et al. 1989) reported that derangements of lipid and 
protein metabolism induced by TNF resemble the metabolic alterations associated 
with injury, infection, or critical illness, in that the energy expenditure was elevated. 
This is further supported by the study of Staal-van den Bredel A J (Staal-van den 
Brekel et al. 1995), hypermetabolic lung cancer patients were found to have 
significant increase in sTNFr (soluble TNF receptor) level when compared with 
normometabolic patients. The weight loss was also related with the elevation of 
sTNFr. Soluble TNF receptors are cytokine-regulatory proteins, mainly released by 
mononuclear cells and polymorphonuclear cells (PMNs), which play a role in a host 
defense to tumor. There is a regulatory role of stimulated PMNs in response to 
TNF-a by initiation of soluble generating TNF receptors (Porteu et al. 1991) and 
those receptors may play a significant role in the regulation of TNF activity 
(Steinshamn et al. 1995). 
There have been little reports on the serum TNF level during cancer treatment. One 
V 
report on the study of soluble TNF receptors presented in sera and released by 
polymorphonuclear cells (PMNs), which the biologic responses of TNF are mediated 
through the receptors (Jablonska et al. 1998) demonstrated that sera from breast 
cancer patients presented with increased level of sTNFr. Surgery treatment resulted 
in higher serum concentration of sTNFr, whereas decreased serum sTNFr levels 
resulted in patients after adjuvant chemotherapy. However, PMNs level of sTNFr 
after treatments, surgery and chemotherapy, showed a decrease. The Author 
suggested that this was due to the surgical removal of the tumor mass resulting in 
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eliminating the effect of tumor cells on the PMNs activity. The function of PMNs 
activity may also be altered by adjuvant chemotherapy. 
2.7.1.2 Interleukin 1 and interleukin 6 
Both interleukin l(IL-l) and interleukin 6 (IL-6) are inflammatory cytokines 
produced by macrophages or lymphocytes in response to endotoxin. 
There are inconsistent reports on the presence of circulating IL-1 level in 
inflammation studies (Moldawer et al. 1987a; Moldawer et al. 1987b). There was a 
study showing no direct effect of IL-1 on protein degradation (Moldawer et al. 
1987c). Tocco-Bradley et al (Tocco-Bradley et al. 1987) had reported that IL-1, like 
TNF, led to an increase in REE，whole body protein turnover and promote 
degradation of muscle protein during infection. However, IL-1 receptor antagonist 
had failed to correct the wasting condition and protein hypercatabolism seen in 
AH-130 tumor bearing mice (Costelli et al. 1995). Apart from the role of inducing 
weight loss, Hellerstein et al. (Hellerstein et al. 1989) demonstrated that IL-1 could 
reduce food intake in meal -fed mice. 
It has been suggested that the production of IL-6 is enhanced by the presence of IL-1 
and TNF-a (Beisel 1991; Evans et al. 1992). Evans et al (Evans et al. 1992) reported 
that the IL-1 and TNF-a induced the transcription and the release of IL-6 gene 
product by tumor cells in vitro. Strassmann et al. (Strassmann et al. 1992) found that 
the IL-6 was a cachectic factor to develop cancer cachexia in a tumor-bearing rats 
model with progressive loss of muscle and fat without sign of appetite loss. And 
when the tumors were resected, rats gained weight with reduced serum level of IL-6. 
The administration of monoclonal antibodies that block the production of IL-6 
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suppressed the development of wasting. However, study has shown that IL-6 cannot 
conclusively induce the wasting syndrome (Soda et al. 1995). The serum level of 
IL-6 in colon tumor bearing mice that did not induce weight loss were lower than 
that in tumor bearing mice that induced weight loss. However, infusion of IL-6 in to 
the former group of mice did not lead to body weight loss. It is suggested that the 
discordant conclusions on whether IL-6 leads to wasting may be due to the 
investigation being done in different tumor species (Toomey et al. 1995). As in 
TNF-a, the production of IL-6 had been found to nicely correlate with tumor burden 
(Fong et al. 1989b; Strassmann et al. 1992). Like the TNF-a, IL-6 plays a role in 
inhibiting LPL activity in the adipose tissue of mice, injection of 11-6 reduced LPL 
activity. Injection of TNF increased serum IL-6 level which further decreased LPL 
activity (Greenberg et al. 1992). The Author suggested that this activity may 
contribute to the loss of body fat stores associated with some cases of cancer 
cachexia. 
Experiments have shown that specific neutralization of cytokines can relieve 
anorexia and weight loss in animal studies (Noguchi et al. 1996; Tisdale 1997)，such 
as the anti-TNF，anti-IL-1 and anti-IL-6. However, those studies have revealed that 
V 
cgichexia can rarely be attributed to any one cytokine but rather is associated with a 
number of cytokines and other cachectic factors (Inui 1999). 
2.7.2 Leptin 
Animal research has suggested that leptin may play an significant role in the 
regulation of energy balance. The role of leptin in the progressive weight loss 
associated with cancer in human is of great concern. 
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In animal study (Pelleymounter et al. 1995), it has been shown that the ob gene 
encodes a hormone, leptin, that is expressed in adipose tissue, regulates body weight 
and fat deposition in rats. Recently, there has been much interest in its role in human. 
Data has demonstrated that leptin might be an afferent signal in a negative-feedback 
loop regulation the size of adipose tissue mass. Leptin is secreted from adipose tissue 
and acts mainly on the hypothalamus (Friedman & Halaas 1998). The level of leptin 
is positively correlated with body fat mass (Nicklas et al. 1997; Polito et al. 2000). 
Among normal weight, obese and weight-losing cancer patients, leptin levels are 
strongly related to fat mass in the body and lower plasma levels have been reported 
among weight losing cancer patients (Considine et al. 1996; Takabatake et al. 1999; 
Wallace et al. 1998). « 
Moreover, increased leptin level results in negative energy balance, while decreased 
level brings in positive energy balance. Leptin can act centrally to decrease food 
intake and modulate glucose (Horowitz et al.) and fat metabolism (Hwa et al. 1997). 
It can reduce appetite and increase energy expenditure (Nicklas et al. 1997) and carry 
out these effects through the central nervous system. In the absence of letpin, such as 
in ob/ob mice, animal fails to restrain their food intake and become obese (Friedman 
� H a l a a s 1998; Inui 1999). 
At the time of the loss of body fat during starvation, it leads to a decrease in leptin 
level, which decreases the activity of anorexigenic neuropeptides, such as CRF 
(corticotropin releasing factor) and promotes the production of orexigenic 
(feeding-stimulatory) neuropeptides, such as NPY ( neuropeptide Y). These changes 
leads to a state of positive energy balance with increase food intake and decrease 
energy expenditure (Figure 2.1). The orexigenic and anorexigenic neuropeptides 
46 
Chapter 2 Literature review 
decrease and increase sympathetic nervous activity respectively, which regulates 
energy expenditure by activating thermogenesis in brown adipose tissue and possibly 
in other sites such as white adipose tissue and muscle. Therefore, if there are factors 
produced by a disease process which induces or mimic the hypothalamic effect of 
excess negative feedback signaling from leptin, sustained anorexia and weight loss 
would be resulted, which is not accompanied by the usual compensatory response. 
(Inui 1999; Mantzoros & Moschos 1998). In a study of weight losing lung cancer 
patients, there was no increase in letpin level. The researchers had suggested that a 
disturbance in hypothalamic responses to leptin might contribute to negative energy 
balance in these patients (Simons et al. 1997). 
As discussed in previous section, TNF-a, IL-1 and IL-6 have been detected in some, 
but not all cancer patients. Administration of these cytokines, either alone or in 
combination, can reduce food intake and lead to different features of cancer wasting 
(Argiles & Lopez-Soriano 1999; Tisdale 1997). Recent studies have reported that 
cytokines have a role in regulation leptin level in human. Mantzoros et al. 
(Mantzoros et al. 1997) suggested that TNF-a system played a role in regulating 
leptin levels. This has been supported by the study done by Zumbach and co-workers 
V 
(Zumbach et al. 1997). On repeated TNF infusion in patients with solid tumor, serum 
leptin level elevated which then returned to baseline level within 24 hours. Moreover, 
serum leptin concentration in cancer patients increased after administration of IL-1 a . 
The level of increase was significantly correlated with IL-1 a dose. Therefore, 
elevation in serum leptin concentration might be one mechanism by which anorexia 
is induced by IL-1 a (Janik et al. 1997). Those cytokines can increase the plasma 
levels of leptin, despite the decrease in food intake that would normally suppress 
leptin expression (Finck et al. 1998). Therefore, such elevated plasma leptin level can 
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lead to anorexia by preventing the normal compensatory mechanisms under the 
effect of decreased food intake (Inui 1999) (Figure 2.2). However, there are studies 
showing that those cytokines can contribute to anorexia even in the absence of leptin 
(Bessesen & Faggioni 1998). Moreover, some tumor-bearing mice (Chance et al. 
1998) and weight-losing cancer human studies have failed to show elevated leptin 
level in them (Simons et al. 1997; Wallace et al. 1998). For unexplained weight loss 
in patients with chronic obstructive pulmonary disease, circulating leptin was 
independent of TNF-a system. This was shown by the results that, lower leptin level 
and higher serum TNF-a was found in COPD patients when compared with the 
healthy controls with higher BMI and percent body fat (Takabatake et al. 1999). The 
inconsistent results suggesting that weight loss is not solely brought about by the 
regulation of leptin and the elevation of leptin level is not conclusively brought about 
by the cytokines. 
V 
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2.8 THE IMPACT OF MALNUTRITION ON CANCER SURVIVAL 
There were only a few studies in the literature, which addressed the long-term impact 
of weight loss during oncological therapy on long-term survival. Despite the 
success of gastrostomy tubes in minimizing weight loss during oncological therapy 
for head and neck cancers, there was no improvement in survival in the tube-fed 
patient group. In Pezner's (Pezner et al. 1987) study on Stage III and IV squamous 
cell carcinoma of the head and neck,.survival was not affected by tube feeding. On 
the other hand there were also studies that suggest a possible adverse effect of weight 
loss on survival. Enig et al (Enig et al. 1986) studied 30 patients with local bladder 
tumors before and during radiotherapy. . When patients were grouped according to 
age, tumour category, histologic grade, treatment, weight/height index and changes 
in weight and anthropometrical parameters, it was found that the weight/height index 
and changes in weight during 4 weeks of radiotherapy had significant influence on 
survival. Also, in van Bokhorst-de van der Schuer's study (van Bokhorst-De van et al. 
1999) on head and neck cancer patients treated by surgery and post-op radiotherapy, 
preoperative weight loss of >5% was found to have a negative effect on the 3-year 
survival probability of male patients. And by the study of Bosaeus et al. (Bosaeus et 
al. 2002)in cancer patients, they found that hypermetabolism and weight loss were 
V 
significant predictors of decreased survival. However, at 4-month follow up, with an 
increase in energy intake after providing nutritional consultation predicted longer 
survival. Therefore, it is of interest that to explore if there is effect of malnutrition on 
the survival in NPC patients established, which is useful for planning long-term 
nutritional care plan for the patients. 
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Table 2.1 Factors contributing to anorexia in radiotherapy patients 
Factors resulting from radiotherapy 
Fatigue 




Nausea and vomiting 
Diarrhea or constipation 
Emotional/psychological responses, i.e. depression and anxiety, to disease or 
treatment 
Changes in lifestyle 
Factors resulting from the disease « 




Adapted from (Grant & Rivera 1995; Holmes 1997) 
V 
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Figure 2.1 Model of neuropeptide activity in response to starvation 
Modified from (Inui 1999) 
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Figure 2.2 Model of neuropeptide activity in response to cancer cachexia 
Modified from (Inui 1999) 
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Chapter 3 Objectives of Study 
The objectives of study are: 
1. To document the body weight alteration in patients with nasopharynx cancer 
during radiation therapy treatment and on long term follow-up. 
2. To investigate the impact of alteration of body weight, in terms of it being a 
potential determinant on long-term survival probability from nasopharynx cancer. 
3. To study the potential determinants of body weight alteration in nasopharynx 
cancer patients before, during and after radiation therapy, in. terms of body 
composition, calorie intake, basal metabolic rate (BMR), total energy expenditure 
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4.1 RETROSPECTIVE STUDY 
4.1.1 Patients 
A retrospective analysis was conducted on 386 patients with non-disseminated NPC 
who first presented to the Department of Clinical Oncology, Prince of Wales Hospital, 
Hong Kong in the period 1987-1989. During this period a total of 453 new cases 
of NPC were seen at the hospital. The clinical records of these patients were 
retrieved for extraction of the following data: pre-radiotherapy body weight, body 
weight at the end of radiotherapy (or within 4 weeks after the last day of radiotherapy) 
and at 3 months, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years after 
radiotherapy. If the follow up visit did not fall on the corresponding time-point, the 
body weight data of the nearest visit was extracted. 67 patients were excluded from « 
the present analysis because of either presence of distant metastases at presentation, 
or incomplete data on any of the following time points: before radiotherapy, at the 
end of radiotherapy, and at 3 months after radiotherapy. The data were entered into 
a database file, which was then merged with another file containing the cancer 
staging and clinical outcome data of the same patient sample. 
4.1.2 Cancer staging 
The patients underwent pre-treatment cancer staging with computed tomography 
scan of the nasopharynx and adjacent regions to determine the T-stage, clinical 
examination including palpation of the neck to determine the nodal metastases status 
(N-stage), chest radiograph and serum alkaline phosphatase level to exclude distant 
metastases. Patients with distant metastastic disease were excluded from this study. 
Cancer staging definitions are according to the International Union Against Cancer 
stage classification of 1987. 
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4.1.3 Cancer treatment 
Radiation therapy was given to the nasopharynx and neck, to a total dose of 66Gy, 
using either 2Gy or 2.5Gy per fraction, 5 fractions per week The radiotherapy ports 
covered the regions at risk of spread from the nasopharynx tumor, including in all 
patients the oropharynx, posterior half of the nasal cavities, the soft palate, the 
posteior half of the tongue. The parotid glands and most of the submandibular 
glands were also irradiated. Patients with tumor extension to the paraphryngeal 
region were given an additional boost dose of radiation of the equivalent of 16Gy. 
Some patients with metastatic neck nodes of >4cm diameter was given 
pre-radiotherapy chemotherapy. 
t 
4.1.4 Outcome endpoints 
The following cancer treatment outcome parameters were used as endpoints for 
analysis: cancer-specific survival, local-regional recurrence of cancer, distant 
recurrence of cancer (distant metastases). Kaplan-Meier plots were used. 
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4.1.5 Determinants 
Two patient groups, those with >10% weight loss at end of radiotherapy and those 
with <= 10% weight loss at end of radiotherapy were compared in the univariate 
analysis, with respect to local-regional recurrence, distant recurrence, and survival. 
In the multivariate analysis, the following potential determinants were entered: 
overall cancer stage (I, II，III，IV), use of pre-radiotherapy chemotherapy, use of an 
additional boost dose of radiation, age, gender, weight loss of >=10% pre-therapy 
bodyweight at completion ofRT, weight loss of >=10% pre-therapy bodyweight at 3 
months post-RT. 
4.1.6 Statistical analysis 
Univariate analysis was performed using the LogRank Test to compare the 
Kaplan-Meier plots of the two patient groups (with >10% and <=10% weight loss at 
end of radiotherapy). Multivariate analysis with stepwise Cox Regression was 
performed using the SAS (Version 6) software. 
» 
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4.2 PROSPECTIVE STUDY 
4.2.1 Patients, oncological treatment, and assessment time points 
Thirty-eight patients (30 men and 8 women) with NPC attending the Department of 
Clinical Oncology, Prince of Wales Hospital, Hong Kong between 1999 and 2000 
were recruited after confirmation of the diagnosis of NPC and before commencement 
of radiotherapy treatment. Their age ranged from 33 years to 71 years (Table 4.1). At 
the beginning, forty-one patients were recruited with 38 of them completed the 
assessment for all time points. All these patients were given standard curative 
courses of radiation therapy with external radiation therapy dose ranging from 66Gy 
to 86Gy in 2Gy per day, 5 treatments per week, for 6.5 to 8.5 weeks. The radiation 
field covered the whole of the nasopharynx, the oropharynx, the posteior half of the « 
nasal cavities, most of the parotid glands and most of the submandibular glands 
throughout the treatment. The hypopharynx was also irradiated during the first 
40Gy of the treatment. Details of patients' treatment scheme were shown in Table 
4.2. 
All patients were assessed at a minimum of 4 time points: at pre-radiation therapy 
(To)，end of radiation therapy (Ti), 2-month after end of radiation therapy (T2) and 
V 
6-month post radiation therapy (T3). Body weight, body composition, dietary record, 
BMR，physical activity questionnaire and subjective assessment of treatment 
complications were assessed at each time point. More detailed assessment was 
made on 11 of the 38 patients in form of assessment at 2 additional time points 
during radiation therapy: at end of week 2 of radiation therapy (Ta) and at end of 
week 4 of radiation therapy (Tb), and also measurement of TNF-a and fasting leptin 
levels on 10 of these 11 patients. At each assessment time point, all the nutritional 
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assessment was completed in one single assessment day with the food record taken 
prior to the assessment day, except at Ti.Table 4.2 shows the recruitment and 
assessment schedule at To. 
This study was approved by the Chinese University of Hong Kong. Written informed 
consent was obtained from the patients (Appendix 1-4). 
4.2.2 Assessment of nutritional intake by food record 
All patients were given instructions on how to record their food intake in an 
interview. Food intake was recorded for 3 days (Appendix 5), which included two 
weekdays and one weekend, within one week prior to assessment day at each time 
( 
point, on a food record form. For time points Ta and Tb, the one-day food record 
(Appendix 6) method was used. Patients were instructed to record all food, beverages 
and snack consumed in the 3 days/ 1 day. The patient first estimated the amount 
using household measures, i.e. teaspoon, tablespoon, bowl and cup. Then, on the 
assessment day，the food items and amounts were verified by the interviewer and 
patient with the help of food photos published in the Hong Kong Adult Dietary 
Survey 1995 (Leung et al. 1995) and by viewing samples of household utensils. The 
V. 
amount of cooking oil was estimated according to the method of preparation of the 
different food items (Table 4.3). The nutrients were analyzed by food table. The food 
table was compiled by the Growth and Nutrition Research Team at Department of 
Pediatrics, the Chinese University of Hong Kong, based on food tables from the 
United Kingdom (Mc Cance et al. 1978)，Mainland China (Institute of Health 1991)， 
Taiwan (Tung et al. 1961) and the United States of America. (Bowes 1994). Product 
information from food manufacturers was also included in the table. 
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In addition, 24-hour recall was used to cross check the accuracy of food intake 
obtained by 1- or 3-day food record. This was performed either on the day of 
assessment, or within 7 days subsequent to the assessment day by telephone 
interview. The subject was requested to recall all the food and drinks consumed in 
the past 24 hours and quantified the amount with reference to household utensils. 
The calorie intake and protein intake analyzed by food table were compared with the 
1988 Recommended Dietary Allowances (RDA) for China. The recommended 
values were age range, sex and activity level matched. The values for "light" activity 
level was chosen for our patients as, during and soon after the radiotherapy period, 
they were usually involved in activities such as standing and walking at a slow pace 
for limited duration, and without work with heavy loading. The values were shown in 
table 4.4. 
The measured protein intake was also compared with the protein requirement for 
cancer patients which, ranged between 1.2-1.5 g/kg bodyweight; we took the average 
of 1.35 g/kg bodyweight for comparison (Curtin University of Technology 1999). 
“4.2.3 Assessment of radiotherapy-induced symptoms 
A questionnaire was used to assess several symptoms related to nutrition and quality 
of life, including the patients' subjective awareness of throat pain, mouth dryness 
(graded nil, mild, moderate and severe), dysphagia (graded nil, mild, moderate and 
severe), loss of appetite, presence of taste change and food preferences (Appendix 7) 
(Chencharick & Mossman 1983). The questionnaire was completed by interview and 
any ambiguous responses were clarified by further questioning. Taste score of 4 taste 
qualities: sweet, salty, bitter and sour were subjectively reported by patients based on 
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a Likert scale of 0-10. Score "0" represents complete loss of such taste quality and. 
Score "10" represents normal taste qualities. Assessment was made at Ti to T3 for all 
patients and also done at Ta and Tb in eleven patients. By the end of study, 
telephone interview was performed to enquire with the patients if any of the above 
adverse effects appeared one month before the start of RT. 
4.2.4 Assessment of Basal metabolic rate 
BMR was measured by indirect calorimetry using a ventilated hood system 
(Deltatrac Metabolic Monitor, Helsinki, Finland). BMR was calculated by the 
following equation: 
BMR (kcal) = 5.5 * V02 (ml/min) (STPD) + 1.76 * Vco2 (ml/min) (STPD)-
• 1.99 * Urinary nitrogen excretion (g/day) 
STPD stands for "standard temperature and pressure, dry gas" 
Urinary nitrogen excretion = 13 g/day 
Measurements in patients were made between 8:30 and 11:00a.m. at an out-patient 
clinic in a quiet environment. Patients were instructed to have at least 10 hours 
overnight fast before the measurement, except for allowing a small amount of water 
before the measurement, and to avoid vigorous physical activity. On each 
�measurement day, the equipment was calibrated using gas containing 95% oxygen 
and 5% carbon dioxide (Deltatrac High-Accuracy Calibration Gas, Helsinki, Finland). 
When the patient arrived at the clinic, the procedure of measuring BMR was as 
follow: 
1) The Patient was asked to rest for 3 to 5 min. 
2) The inside of the canopy was cleaned with alcohol preparation and allowed to dry. 
A new sampling line would then be connected with both the calorimeter and the 
air inlet of the canopy. 
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3) Then, the patient lay in a supine position on the bed. The head of the patient would 
be covered with the canopy. The plastic bag around the edge of the canopy was 
folded under the patient's pillow to prevent air leakage through the canopy. 
4) The patient was instructed to keep awake with normal breathing throughout the 
whole measurement period. 
5) Measurement was started by pressing the START/STOP key on calorimeter. The 
measurement period lasted at least for 25 minutes The flow through the canopy 
was constantly at 40 L/min. 
In the beginning of measurement hyperventilation may cause erroneous results. 
This situation would normally be over in 5 to 10 minutes. Therefore, the data 
collected in the first 5 minutes were suppressed (using the ARTFACT 
* SUPPRESSION function) and would not be taken average for final result. Thus, 
the actual valid measurement time of steady state was 20 minutes. 
6) At 25 minutes, the measurement was terminated by pressing START/STOP key, 
and then END key. The patient's BMR report was then generated by pressing 
END REPORT key. 
Flow calibration was done in every 2-3 months with 95% ethanol at RQ between 0.6 
� a n d 0.7. Then the new flow rate would be inputed to the calorimetry with the new 
adjustment falling within 40 L/min 土 4 L/min, otherwise, this calibration test would 
be done again. The pressure calibration was done in every 6 months. 
4.2.5 Assessment of total energy expenditure and energy balance 
Total energy expenditure (TEE) was measured by conducting a physical activity 
questionnaire used for Chinese population (Liu et al. 2001)，which covers 
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occupational, general household, care taking, sports and leisure activities. This 
questionnaire was based on modified Yale Physical Activity Survey (YPAS) 
questionnaire (Dipietro et al. 1993)，which was originally applied to older American 
adults. In order to adapt it to the Hong Kong population, some activities had been 
omitted and new items were added, i.e. playing mahjong, karaoke and several sports 
activities. The intensity codes of the new items added were matched with the 
databases (McArdle et al. 1991; Taylor et al. 1978) used for YPAS questionnaire and 
Zutphen study (Caspersen et al. 1991) (Appendix 8). This modified questionnaire 
had been validated with healthy Hong Kong adults by measuring BMR with indirect 
calorimetry and multiplying by the physical activity level (PAL) quoted from 
published studies using the doubly-labeled water method and also from 
FAO/WHOAJNU to obtain the TEE. Intraclass correlation coefficient of reliability 
ranges from 0.7 to 0.8 for all subject groups, including healthy adults, the elderly, 
renal disease adults and cancer adults. The mean estimated TEE from the 
questionnaire was not significantly different form the mean value derived from 
measure BMR x PAL (Liu et al. 2001). 
The questionnaire was administered by interview. The following verbal questions 
“ w e r e used for each activity items: "Are you doing that particular activity each day? 
How many times that you do the activity each day?" or "How frequent that you do 
that particular activity during last week?" and “ How long do you spend on that 
activity each time?" The frequency and time duration were recorded on the 
questionnaire by interviewer. By multiplying the energy intensity code with the 
frequency and time duration (min), the weekly energy expended in that particular 
activity was calculated. Using 24-hour period as a basis, activities in the hours that 
had not been accounted for by the questionnaire were assumed to be very light 
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activities with an intensity code of 1.3. The intensity code for sleep is 1.0. 
Summation of weekly energy expended in all activities reported, sleeping and hours 
that had not accounted for, resulted in weekly total energy expenditure: 
TEEw 二 (intensity code x frequency x time interval) + Sleeping time x 7 x 1.0 + 
(24-total hour recalled) x 60 x 7 x 1.3 
By dividing the TEEw by 7, daily total energy expenditure was obtained: 
TEEd= TEEw" 
As the intensity code was based on a resting metabolic rate (RMR) of 60 kcal/hr for a 
60-kg subject, body weight had to be corrected in obtaining individual energy 
expenditure by multiplying the TEEd by a weight factor: bodyweight/60 kg.; 
Weight-corrected TEEd = TEEd x bodyweight/60 
« 
Energy balance was determined by subtracting total energy expenditure measured by 
physical activity questionnaire from energy intake estimated by food record. 
4.2.6 Assessment of body composition 
Fat mass (FM), lean mass (LM) and bone mineral content (BMC) were measured 
using a dual X-ray bone densitometer (QDA 4500 Elite X-ray Bone Densitometer, 
V 
Hologic Inc., Waltham, USA). The fat-free mass (FFM) was the sum of LM and 
BMC. Total body mass (TBM) was the sum of FM and FFM. Percent FM was 
calculated as follow: 
FM% 二 FM X 100/TBM 
Detailed procedures are listed as follow: 
Quality Control 
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Quality Control (QC) is a procedure for verifying that the densitometer is performing 
properly. Therefore, QC was done each day before the first patient was scanned. 
Firstly, using the spine phantom, auto scan/analyze was performed to obtain OC 
results. The results would then be added to the QC database. Several scans would be 
plotted with the parameters: BMD (bone mass density), BMC and Area, respectively. 
The QC was said to be successful if the plot of those parameters lied within the upper 
and lower limits. After that, using the tissue bar, auto scan was performed to 
complete the QC. 
Whole Body Examination 
Before the examination, patients were told to change their clothes and wear the gown 
and trousers provided. The patients were verified with no removable metal/plastic 
objects on their body, i.e. snaps, belts, underwire bras, watches etc. The Patient's 
body weight and height were measured by standard balance and the parameters were 
added to patient data of the scan. 
“Patient Positioning » 
The Patient lay supine on the table with the head at the right end of the table (for 
operator faced the table). 
The Patient lay straight, at the center of the mat, and was positioned entirely within 
the scan limit borderline just inside the outer edge of the mat. 
The Patient's legs were rotated inward until the toes touched. A tape was placed 
around the feet to maintain the rotation. 
The Patient's arms were placed at the patient's side, palms down, with a separation 
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from the thighs. There was space between the patient's arms and sides whenever 
possible. 
Scanning 
During scanning, patient refrained from speaking and any body movement. 
Whole Body option was chosen for scanning. The Length of Scan and the Width of 
Scan was approximately 76 inches (193 cm) and 27 inches (69 cm), respectively. 
The dimensions of the collimator was 4 x 0.8 inches. The number of lines scanned 
was 150 and the number of samples per line was 327. Line Spacing, the distance 
between each step of the scanner arm, was 0.513 inches (1.303 cm). And Point 




Contrast and brightness of the image was adjusted with the up/down arrow keys to 
obtain the best definition of key anatomical features. 
Region Selection ‘ 
� T h e scanned image and yellow lines defining regions would appear on the screen. 
The regions set for analysis were set as follow with <+> <-> < P g U p � a n d <PgDn> 
keys: 
The horizontal line above the shoulders was just below the chin. 
The vertical lines at the shoulders were set between the head of the humerus and 
scapula at the glenoid fossa. 
The vertical lines on either side of the spine were moved close to the spine, angled to 
match the curvature. 
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The small horizontal line was approximately at the level of T12-L1. 
The horizontal line above the pelvis was just above the crest of the ilium. This line 
could be extended out at the sides to include soft tissue in the chest and waist. The 
soft tissue from the trunk should not be included with the arms whenever possible. 
The angles lines below the pelvis bisected both femoral necks. 
The vertical line between the legs was adjusted to be between the feet. 
The vertical lines lateral to (outside of) the legs was adjusted to include as much of 
the soft tissue in the thighs as possible without including the patient's hand (finger). 
Report Generation 
When region lines were correctly positioned, the system would analysis the data by 
pressing <End>. A report screen would be displayed (Appendix 9) after the analysis 
was completed. The report was then printed out. 
4.2.7 Measurement of cytokines 
Serum collection 
Blood was taken on the day of BMR measurement. The blood sample was 
centrifuged for 20 minutes at 3000 rpm. The serum was removed and aliquoted in 
V 
two tubes. The serum samples were stored at -20°C 
Principle of the Assay for TNF-a and Human Leptin 
Both measurements employed the quantitative sandwich enzyme immunoassay 
technique. The microplate of each assay was pre-coated with the corresponding 
antibody, i.e. antibody of TNF-a was pre-coated on TNF-a measurement wells, 
whereas antibody of Human Leptin was pre-coated on Human Leptin measurement 
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wells. Standard solutions, samples and Controls (if available) were pipetted into the 
wells and any TNF-a or Human Leptin present was bound by corresponding 
immobilized antibody. After washing away any unbound substances, an 
enzyme-linked antibody specific for TNF-a or Human Leptin was added to the wells. 
After a second wash to remove any unbound antibody-enzyme reagent, a substrate 
solution was added to each well. Following an incubation period, an Amplifier 
Solution was added for TNF-a measurement to general color development. Then, an 
acidic Stopping Solution was added to the wells to stop further color development. 
The color developed was proportionate to the amount of TNF-a or Human Leptin 
present，, a quantified by dual wavelength absorbance measurement. 
4.2.7.1 Serum TNF-a 
Serum TNF-a was measured by the quantitative sandwich enzyme immunoassay 
technique using commercial kits (Human TNF-a immunoassay kit, R & D Systems 
Inc., USA). The limit of sensitivity was 0.18pg/mL. Detail procedures are described 
as follow: 
Reagent preparation & assay procedure 
‘ A s the unopened kit and samples were stored at 4°C and -20°C respectively, all those 
reagents and samples were brought to room temperature before use. The standards 
and samples were assayed in duplicate. 
Preparation of TNF-a Standard 
The TNF-a Standard was reconstitute with 1 mL of Calibrator Diluent HD6J. This 
reconstitution produced a stock solution of 32pg/mL. The standard was left for 15 
minutes with gentle agitation. 
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After that, 500|li1 of HD6J Diluent was pipetted into each tube (a total of seven). 
Then the stock solution was used to make a serial dilution as shown in Figure 4.1. 
Each tube was mixed thoroughly before the next transfer. A total of eight standard 
solutions were prepared: 32pg/mL, 16pg/mL, 8pg/mL, 4pg/mL, 2pg/mL, Ipg/mL, 
0.5pg/mL and Opg/mL. 
2. 50 |liL of Assay Diluent HDl-11 was added to each well of microplate by 
multichannel pipette. 
3. 200 |liL of standard solutions or samples were added per well. The adhesive strip 
and parafilm were used to seal the whole plate tightly and then it was incubated for 
20 hours at 2-8�C. 
4. On the next day, 30 minutes before the end of incubation time. The Wash Buffer 
was prepared by diluting lOOmL of Wash Buffer Concentrate with deionized water to 
prepare 500 mL of Wash Buffer. It was mixed well. 
5. After 20-hour incubation, the parafilm was removed. The adhesive strip was 
removed and adhered to the underside of the wells to avoid the possibility of wells 
becoming dislodged during the decanting and rapping operations. 
6. The plate was inverted and the content in the wells was decanted. Then the plate 
was grasped firmly, inverted and rapped smartly on blotting paper for at least 5 times 
� 7 . Microplate washer was rinsed for several times before use. The Wash Buffer was 
then connected to the microplate washer. The plate was washed with the buffer by 
the washer for 4 times. After the last wash, the plate was inverted and rapped smartly 
for 10 times on blotting papers to remove excess Wash Buffer. The microplate 
washer was rinsed again after use. 
8. 200 |liL of TNF-a Conjugate was pipetted to each well. The plate was covered 
with a new adhesive strip and parafilm. It was incubated for 3 hours at room 
temperature. 
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9. During this incubation time，the Substrate Solution was prepared. The lyophilized 
Substrate was reconstituted in 6 mL of Substrate Diluent. It was then mixed 
thoroughly. The solution was left for later use. And the rubber stopper was discarded 
after reconstitution. 
10. After 3-hour incubation, the adhesive strip was removed and adhered to the 
underside of the plate. The washing procedures were repeated as stated in step 6 to 7. 
11. 50 fO-L of Substrate Solution was added to each well and the plate was covered 
tightly with a new adhesive strip and parafilm. It was incubated at room temperature 
for one hour. 
12. During the incubation time, the Amplifier Solution was prepared. The lyophilized 
Amplifier was reconstituted in 6 mL of Amplifier Diluent. It was left for at least 10 
minutes before use. The rubber stopper of the Amplifier Solution was then discarded. 
13. After the incubation time, 50 \xL of Amplifier Solution was pipetted into each 
well. The plate was then covered with a new adhesive strip and parafilm. It was left 
for 30 minutes at room temperature. At this moment, colour change would be 
developed, from colorless to maroon. 
14. After 30 minutes, 50 |iL of Stop Solution were pipetted into each well. The 
addition of Stop Solution would not affect the color in the well. The optical density 
� o f each well was read at 490 nm within 30 minutes using ELISA plate reader. 
Calculation of results 
The duplicate readings for each standard solutions and samples were averaged. The 
optical density for the standards was plotted against the concentration of the 
standards. The best line was obtained by linear regression analysis. Serum TNF-a 
concentration of each sample was obtained from the standard curve. 
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4.2.7.2 Serum Human Leptin 
Serum leptin was measured by the quantitative sandwich enzyme immunoassay 
technique using commercial kits (Human Leptin ELISA Kit, Diagnostic Systems 
Laboratories, Inc., USA). The limit of sensitivity was 0.05ng/mL. Detail procedures 
are described as follow: 
Reagent preparation & assay procedure 
As the unopened kit and samples were stored at 4°C and -20°C respectively, all those 
reagents and samples were brought to room temperature before use. The standard 
solutions and samples, except Controls, were assayed in duplicate. 
1 The 60 mL Wash Concentrate, containing buffered saline with a nonionic 
detergent, was diluted 25-fold with deionized water. 
2 25 )iL of each Human Leptin Standard A to F (containing 0 ng/mL, 0.5 
ng/mL,2.5 ng/mL, 10.0 ng/mL, 25.0 ng/mL, 50.0 ng/mL recombinant human leptin 
in a protein-based buffer respectively), two Human Leptin Controls containing low 
and high concentrations of human leptin in protein-based buffer, and samples were 
added into appropriate wells of the plate 
3 100 \xL of Assay Buffer E, containing protein-based buffer, was added to each » 
well The plate was covered well. 
4 The plate was incubated at room temperature for 2 hours with shaking at a fast 
speed (500-700rpm) on an microplate shaker. 
5 The microplate washer was rinsed for several times. Then, each wells was 
washed with the Wash Solution using the microplate washer for 5 times. After that, 
the whole plate was inverted and the content in the wells was decanted. Then the 
plate was grasped firmly, inverted and rapped smartly on blotting paper for several 
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times until no bubbles were in the wells. 
6 Preparation of Antibody-Enzyme Conjugate Solution 
The Antibody-Enzyme Conjugate Concentrate, containing anti-human leptin 
antibody conjugated to horseradish peroxidase in a protein-based buffer with a 
non-mercury preservative, was diluted at a ratio of 1 part into 50 parts of Assay 
Buffer E. For an entire plate, 240 [iL of the Antibody-Enzyme Conjugate 
Concentrate was pipetted in 12 mL of the Assay Buffer E and was mixed well. 
7 100 ^L of the above Antibody-Enzyme Conjugate Solution was added to each 
well and the plate was covered well. 
8 The plate was incubated at room temperature for 1 hours with shaking at a fast 
speed (500-700rpm) on a microplate shaker. 
9 Step 5 was repeated to wash the plate. 
10 100 i^ L of TMB Chromogen Solution was added to each well and the plate was 
covered well. 
11 The plate was incubated at room temperature for lOminutes with shaking at a 
fast speed (500-700rpm) on a microplate shaker. Direct exposure to sunlight was 
avoided. 
12 100 [xL of Stopping Solution (0.2M sulfuric acid) was added to each well. 
’ 13 The optical density of each well was read at 450 nm within 30 minutes using 
ELISA plate reader. 
Calculation of results 
The duplicate readings for each standard solutions and samples were averaged. The 
optical density for the standards was plotted against the concentration of the 
standards. The best line was obtained by linear regression analysis. Serum Leptin 
concentration of each sample was obtained from the standard curve. 
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Statistical analysis 
Data was analyzed with SPSS software version 10.0 for Windows (SPSS Inc., 
Chicago, IL，US). 
Multiple Comparisons were performed to test the differences of the same variable 
across different time points. Paired sample t-test was used to compare the differences 
of measured and predicted values of BMR. Pearson's correlation was used to test 
the correlation between anthropometrical parameters, energy expenditure and dietary 
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Table 4.1 NPC Patients' characteristics 
Sample size (M/F) 38 (30/8) 
Mean age (range) 46 (33-71) 
Treatment (RT) length 
- 6 . 5 w e e k 23 
- 8 . 5 w e e k 
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Table 4.2 Patients' treatment scheme 
Total number Age RT only RT+NPB RT+CT RT+NPB+CT 
(men/women) -
38 33-71 15 15 6 2 
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Table 4.3 Estimation of oil consumed together with foods prepared 
Food items Oil estimated, tablespoon 
Butter spread for 50 g bread 0.5 
200 g fried noodle ^ 0.5 
100 g boiled vegetable with oil added 0.2 
100 g stir fried vegetable 0.5 
100 g steam fish, no sauce 0.3 
100 g steam fish, with sauce 0.5 
100 g fried fish 0.8 
50 g stir fried meat 0.5 
50 g deep fried meat 1.5 
240 ml soup 0.3 
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Table 4.4 Recommended dietary allowances for energy requirement and protein 
intake for china 
Category* Energy(kcal) Protein (g) 
Adult male female male female 
18 years� 2600 2300 80 70 
45 years� 2400 2100 75 70 
60 years � 2200 1900 75 65 
70 years- 2000 1800 70 60 
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Figure 4.1 Serial dilution in determining serum TNF-a level 
500|LIL 
s td . 500|LIL 500|LIL 500|LIL 500)AL 5 0 0 ^ L 
32pg/mL 一 
stock " 
™ " ~ ~ I f ^ 1 
^ ^ ^ ^ ^ ^ jj^jjjfejjjjj^H 
16pg/mL 8pg/mL 4pg/mL 2pg/mL Ipg/mL 0.5pg/mL Opg/mL 
The serial dilution of TNF-a standard. '^ 500)liL of Calibrator Diluent was pipetted in 
each tube first. Then, ^^ 500|LIL of stock solution was pipetted into the first tube to make 
the standard of 16pg/mL. The content of the first tube was mixed thoroughly before the next 
transfer of 500)LIL to the second tube. The remaining different concentrations of standard 
were made as indicated by the arrows. Each tube was mix thoroughly by pipetting up and 
down for several times before the next transfer. The undiluted standard served as the high 
standard (32pg/mL). The Calibrator Diluent served as the zero standard (0 pg/mL). 
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5.1 RETROSPECTIVE STUDY 
5.1.1 The 5-year profile of bodyweight change during and after the end of 
radiotherapy 
The serial bodyweight of 386 NPC patients at pre RT, end of RT, 3 months post end 
RT (mth3), 6 months post end RT (mth6), and 2 to 5 years post end RT, i.e. yr 2-5， 
are shown in Figure 5.a. The serial percentage change of body weight is shown in 
Figure 5.b. Body weight showed a trend of significant decline by the end of RT and 
troughed at 3 to 6 months after RT. After that, body weight gradually recovered. 
A subset of 226 patients with complete information on body weight at each 
post-treatment anniversary was further analysed. (Figure 5.c & Figure 5.d). It 
confirmed that body weight reached the lowest point at 3 months post end RT. It 
started to increase progressively thereafter 6 months post end RT, 2 and 3 year post 
end RT, but even at these late time-point was still significantly lower (p<0.001) than 
that at pre RT. It was until 4 year after post end RT, that body weight returned to the 
pre-RT level. 
When patients were segregated into two groups according to a weight loss of >=10%, 
or <10%, at end-RT, it was found that in the group of patients with weight loss >= 
10%, the BMI and age were significantly higher than those with body weight loss 
of < 10% (BMI: 23.2 kg/m2 vs. 21.3 kg/m^; age:.49.1 years vs. 45.5 years, p<0.05). 
The stage of NPC was not significantly different between these two groups. 
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5.1.2 Analysis on relation between weight loss and survival 
5.1.2.1 Patient and cancer stage 
There were 284 males (73.6%) and 102 females. 
The cancer T-stage distribution was: Tl: 108 (28%), T2: 104 (26.9%), T3 118 
(30.6%), T4: 56 (14.5%). 
The cancer N-stage distribution was: NO 114 (29.5%), Nl: 167 (43.3%), N2: 56 
(14.5%), N3: 49 (12.7%). 
The overall cancer stage distribution was: Stage I: 49 (12.7%), Stage II 94 (24.4%), 
Stage m 143 (37%), Stage IV (25.9%). 
k 
5.1.2.2 Percentage ofpatients with weight loss at end of radiotherapy 
100 patients (25.9%) had a weight loss of >10% of pre-RT body weight at the end of 
radiotherapy. 132 patients (34.2%) had a weight loss of >10% of pre-RT body 
weight at 3 months after completion of radiotherapy. 
5.1.2.3 Cancer treatment outcome 
A total of 93 patients (24.1%) had local and/or regional recurrences 
V 
•A total of 98 patients (25.4%) had distant recurrence 
A total of 131 patients (33.9%) had died of NPC 
5.1.2.4 Univariate analysis 
Univariate analysis shows that there was no significant difference between the >10% 
weight loss group and the <=10% weight loss group with respect to cancer survival, 
local-regional recurrence, and distant recurrence (Figures 5.e to Figure 5.g). 
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5.1.2.5 Multivariate analysis 
Multivariate analysis with stepwise Cox Regression model shows that, 
For cancer death, the significant determinants are: 
-advanced overall cancer stage (p=0.001), 
-advanced age (p=0.0013), 
-and lack of radiation boost dose (p=0.0391). 
Percentage weight loss of >10% at end of radiotherapy and at 3 months 
post-radiotherapy were not significant determinants. 
For local-regional recurrence of cancer, the determinants are: 
-advanced overall cancer stage (0.0034) 
• - and advanced age (p=0.0043). 
Percentage weight loss of >10% at end of radiotherapy and at 3 months 
post-radiotherapy were not significant determinants. 
For distant failure, the determinants are: 
-male sex (p=0.0384) 
-and lack of radiation boost dose (p=0.015). 
� P e r c e n t a g e weight loss of >10% at end of radiotherapy and at 3 months 
post-radiotherapy were not significant determinants 
Thus weight change was not an independent prognostic factor on cancer recurrence 
and cancer survival. 
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5.2 PROSPECTIVE STUDY 
5.2.1 The profile of nutritional measurements during radiotherapy 
5.2.1.1 Bodyweight and body composition before and during RT 
The bodyweight and body composition of 38 patients at pre RT (To) and end RT (Ti) 
is shown in Table 5.1. 
The mean BMI was 24.2士3.9 kg/m^ (range 14.7-30.8 kg/m^) before commencing of 
RT. Ten patients had normal BMI, 25 patients were overweight and 3 of them were 
underweight. There was a significant reduction in the mean BMI at end RT to 
21.5±3.7 kg/m^ (range 13.7-27.9 kg/m^), which was significantly lower than that at 
pre RT (p<0.001). 
t 
For individual patients, there was generally a sharp downward trend of bodyweight 
change during RT, from 63.3±11.4 kg (mean 土 S.D.) to 56.5±10.9 kg. At end-RT, 
there were as much as 87% (33/38) of patents with weight loss > 5% and 53% (20/38) 
of patients with loss > 10%. 
At To (before radiotherapy), the mean body fat mass of the patients was 15.1 ±4.9 kg 
‘(range 5.2-23.2 kg), whereas mean lean body mass was 46.2土8.3 kg (range 26.4-58.5 
kg). By Ti, when the patients had sustained a mean body weight loss of 6.9 kg and a 
> 10 % weight loss, the corresponding mean loss in body fat mass was 2.7 kg and the 
loss in lean body mass was 4.2 kg (Table 5.2). The body fat mass and lean body mass 
after radiotherapy were both significantly lower than that at pre RT (p<0.001). 
The detailed profile of body weight change during week 2 and week 4 of the 6-8 
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week course of radiotherapy were further studied in 11 patients (Figure 5.1 and 5.2). 
There was a significant linear downward trend of body weight change during this 
early part of RT. Although there were a few patients showing increase in body weight 
at week 2 of RT, most of them had further decrease in body weight at week 4 of RT. 
Figure 5.3 shows the median percentage body composition change during week 2-4 
of RT. Both median percentage change of lean body mass and body fat displayed a 
significant downward trend during week 2 to 4 of RT, with greater median 
percentage loss of body fat at end RT. 
Relation between anthropometrical data at yre RT and bodvweisht chanse durins RT 
(i-e. T,-Tn) 
•Weight loss by the end of RT did not correlate with pre-RT bodyweight (r = -0.022)， 
pre-RT BMI (r = -0.051) and pre-RT body composition (r = -0.014 for lean mass; r = 
-0.029 for body fat mass). 
5.2,1,2 Calorie intake before and during RT 
Patients' calorie intake at pre RT was 1857±411 kcal, which was 77% of RDA China. 
By the end of RT, their intake had declined to 11681549 kcal, which was 
，、significantly lower than the pre RT intake value (p<0.001) (Table 5.4). 
In terms of dietary intake, by the completion of radiotherapy, thirty-four out of 38 
patients had decreased diet intake, mean percentage drop was — 42.0% (ranged 
from -4.2 % to -84.4%). Only 10.5 % of patients had energy intake greater than 80 
% of RDA. According to the estimation of energy requirement of cancer patients, 
which is BMR times 1.5，only 26 % of patients had energy intake greater than 80 % 
of this estimated requirement at end RT. 
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Before radiotherapy (To), 53.9 土 8.7 % of energy intake was derived from 
carbohydrate, 17.8 士 4.0 % from protein and 59.9 士 19.9 % from fat. By end RT (Ti), 
percentage of energy derived from carbohydrate increased to 60.7 %, whereas 
percentage energy derived from protein decreased significantly, from 17.8±4.0 to 
14.6±4.4; p<0.05. The protein intake at Ti (44±37kg) only met 58% of RDA, and 
61% of cancer patients' requirement. The percentage of energy derived from fat did 
not change significantly. 
The profile of calorie intake during the early part (week 2-4) of radiotherapy was 
further studied in 11 NPC patients (Figure 5.4). There was a great variation of total 
•calorie intake during week 2 to 4 of RT. Figure 5.5 shows the median calorie intake 
per kg body weight at each time point during RT. No significant difference was 
found between different time points of calorie intake. 
Relation between calorie intake and bodvweisht change during RT (i.e. Ti-Tn) 
The percentage weight loss during RT correlated with the percentage change of 
calorie intake during R T (i.e. T i - T q ) (r = 0.322，P<0.05). Neither the absolute value 
， . o f calorie intake at pre RT and end RT, the calorie intake per kg bodyweight at pre 
RT and end RT, the protein intake or protein intake per bodyweight at pre RT and end 
RT, correlated with the weight change during RT. 
5,2.1,3 Energy expenditure before and during RT 
The BMR at pre RT (To) was 1406 kcal/day. BMR after completion of RT was 
significantly lower than that at To (1230kcal, p<0.001). When the BMR was 
corrected for body weight, no significant difference was observed at end RT (Ti). 
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The value was kept at approximately 22 kcal/kg bodyweight. For BMR per kg lean 
body mass, no significant difference was found at end RT (Ti) compared to pre-RT. 
(Table 5.5) 
The profile of basal metabolic rate change during the early part (week 2-4) of 
radiotherapy was further studied in 11 patients, Figure 5.6. Majority of patients have 
decreased BMR by week 2 of commencing RT. Median BMR per kg lean body mass 
showed there was a steady level from week 2 of commencing RT to the end of RT 
(Figure 5.7). 
Total energy expenditure (TEE) at pre RT was 2494±729kcal/day and was 
• significantly decreased to 1769±430kcal/day (pO.OOl) at end of RT. (Table 5.5) 
The profile of total energy expenditure during the early part (week 2-4) of 
radiotherapy was studied in 11 NPC patients, Figure 5.8. Some patients showed a 
slight increase in total energy expenditure by the second week of commencing RT 
but generally most of them had a slight decrease by the fourth week of treatment. 
V, 
Relation between enersy expenditure and bodyweisht chanse during RT (i.e. Ti-Tn) 
‘Percentage weight loss during RT correlated with the percentage change of total 
energy expenditure during RT (r = 0.629，p<0.001). Neither BMR, BMR per kg 
bodyweight or BMR per kg lean body mass at pre RT or at end RT correlated with 
the weight change. 
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5.2.1.4 Energy balance before and during RT 
The calorie intake at pre RT and end RT was significantly lower than the total energy 
expenditure (p<0.001), implying negative energy balance. NPC patients experienced 
an energy deficit of 600kcal/day at pre and end RT (Table 5.6). 
Relation between enersv balance and bodvweisht chanse durins RT (i.e. Ti-Tn) 
Although there was a marked degree of weight loss during RT and there was 
negative energy balance before and at the end of RT, Weight loss during RT did not 
have a significant correlation to the degree of negative energy balance at pre RT 
(r=0.166) and at end RT (r=0.038). 
‘5.2.2 The profile of nutritional measurements during the 6-moiith period after 
radiotherapy 
5.2.2.1 Body weight and body composition during the 6 months after radiotherpay 
In terms of the mean body weight of the whole group of patients, there was a further 
slight decrease of mean bodyweight from end RT to 6 months post RT (Ti to T3). 
Thus the mean bodyweight at 6 months post RT was still significantly lower than that 
�� before radiotherapy (To). (Table 5.1) 
At 2-month post end RT, there were more patients (58%, 22/38) who had further 
.weight loss since end RT, than patients who experienced weight gain (42%, 16/38) 
since end RT. By 6 months post RT, there were still 50% of patients who had 
sustained further weight loss compared to end RT, while the rest had weight gain 
compared to end RT. 
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During the recovery time after the completion of RT, lean body mass increased 
slightly at 2-month post end RT and the increase became significant at 6-month post 
end RT (43.3kg vs. 42.1kg, p<0.001), but was still significantly lower than that at pre 
RT (p<0.001). Body fat mass continued to decrease after end RT. At 6-month post 
RT, it was significantly lower than that at end RT (10.4kg vs. 12.4 kg, p<0.001). 
Relation between anthroyometrical data at end RT and bodyweight chanse during 
subsequent 6 months (i.e. T^-Ti) 
Anthropometrical measures at end of RT (Ti) have a significant negative correlation 
with the weight change from end RT to 6 months post RT, in terms of bodyweight (r 
=-485，p<0.01), BMI (r = -0.522, p=0.001)，percent body fat (r = -0.570, pO.OOl). 
.However, percent lean body mass (r = 0.544, p<0.001) is positively correlated with 
the weight change at 6 months post RT. 
Most of the anthropometrical parameters at 2 months post RT did not significantly 
correlate with weight change at 6 months post RT (T3), except percent body fat (r = 
-0.399, p<0.05) and percent lean body mass (r = 0.377，p<0.05). 
v‘ 
m 
Comparison of anthroyometrical data between patients who had weight loss vs 
.patients who had weisht sain after RT 
Comparisons were made between patients with weight gain and continued weight 
loss from end-RT to 6-month post end RT. Patient with weight loss had higher BMI 
(p<0.01) and percent body fat (p<0.05) at both pre and end RT time-points than the 
weight gain patients. On the contrary, they had lower percent lean body mass at 
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pre-RT and end RT (p<0.01) than the weight gain patients. Continued weight loss 
patients also had a higher pre treatment (To) body weight (68.8 kg vs. 57.9 kg, 
p<0.01) and end treatment (Ti) bodyweight (62.2 kg vs. 50.8 kg, p=0.001) than 
patients with weight gain. (Table 5.3) 
In the patients who gained weight between end RT and 6 months post RT, 17/19 of 
them had increased lean body mass (2.10kg 土 2.14kg) during this period and 9 of 
them had increased body fat mass (1.23kg±1.16kg). In the patients who continued to 
lose weight from end RT to 6 months post RT, all of them experienced body fat loss 
(-3.97kg ±2.27kg), while half had increased lean body mass. (Table 5.3) 
* 5.2.2.2 Calorie intake during the 6 months after radiotherapy 
By 2 months after radiotherapy (T2), calorie intake had significantly increased 
(1960±544kcal, compared to end RT with p<0.001) and by 6 months after 
radiotherapy (T3 )，it had returned to a level similar to that at To. By 2 months and 
6 months post end RT, over 80% and 90% of patients respectively had intake greater 
than 80% of the recommended daily allowance (RDA) (Table 5.4). 
’ By 2-6 months after completion of RT (T2 and T3), carbohydrate, protein and fat 
intake of patients had increased significantly when compared with the intake 
immediately after radiotherapy (T!)，to a level similar to that pre-radiotherapy. 
“Carbohydrate intake was 252±69g and 233±60.8g at T2 and T3, respectively 
(p<0.001 vs. Ti). Percentages of calorie derived from carbohydrate were 
approximately kept at 50% at T2 and T3. Protein intake at T2 and T3 were well 
above the protein requirement in RDA China and for cancer patients (Curtin 
University of Technology 1999). Protein intake per kg bodyweight at T2 and T3 
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were 1.54±0.54g/kg and 1.52±0.46g/kg，respectively, which were significantly 
higher than that at end of RT (Ti) (p<0.001). Fat intake was 66.8±23.9g and 
63.7±18.2 at h and T3, respectively (p<0.05 vs. Ti). Approximately 30% of total 
calorie intake was derived from fat at these two time points (Table 5.4). 
Relation between calorie intake at end RT and bodyweisht change durins the 
subsequent 6 months (i.e. T^-Tr) 
The percentage body weight loss at 6 months after RT showed significant correlation 
with the low dietary intake per kg body weight at end RT (r = 0.361, p<0.05).. 
Neither the absolute value of calorie intake, protein intake or protein intake per 
bodyweight at end RT and at the subsequent 2 and 6 months correlated with the 
• percentage weight loss. 
5.2,2.3 Energy expenditure during the 6 months after radiotherapy 
BMR at 2 months after radiotherapy (1220kcal) and at 6 months (1199kcal) post end 
RT (T2 and T3) were significantly lower than that before commencing of RT 
(p<0.001) (Table 5.5). When the BMR was corrected for body weight, no significant 
difference was observed during the recovery time period (T2 and T3) and was also 
�， k e p t at 22kcal/kg bodyweight. However, BMR corrected for lean body mass 
showed a significant decrease at 2 months (T2) (28.7kcal/kg lean mass) and 6 
months (T3.) (28 kcal/ kg lean mass) when compared with that at pre RT (30.7kcal/kg 
lean mass, p<0.01). 
By 2-month and 6-month post end RT, patients' TEE was approximately kept at 
2000kcal/day, which was significantly higher than that at end RT (p<0.001). 
Patients' TEE was the lowest by the time of completion of RT (Table 5.5). 
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Relation between enersy expenditure and bodvweisht loss durins the subsequent 6 
months (i.e. 
Percentage bodyweight loss during the 6 months post-RT correlated with BMR per 
kg body weight at end RT (Ti) (r = 0.497, p<0.01) and TEE at Ti (r = -0.413， 
p 二 0.01). 
5.2,2.4 Energy balance during the 6 months after radiotherapy 
Energy balance was achieved at 2 months after radiotherapy, when calorie intake had 
increased to meet total energy expenditure at T2. However, at 6 months after 
radiotherapy, calorie intake became significantly lower than total energy expenditure 
‘(p<0.05) with a mean energy deficit of 200kcal/day (Table 5.6). 
Relation between enersy balance and weisht loss durins the subsequent 6 months 
(LeJjzTiX 
Negative energy balance at end RT showed a significant correlation with the weight 
loss during the subsequent 6 months (r = 0.392, p<0.05). 
5.2.3 Radiotherapy-induced Symptoms 
5.2.3.1 Profile of symptoms after RT 
At pre RT, none of the patients had throat pain, dysphagia, mouth dryness, taste 
alteration or appetite loss. 
The frequencies of these radiotherapy-related symptoms at end RT, 2-month post RT 
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and 6 month post RT of 38 patients are shown in Figure 5.9-5.11. 
The most common symptom was throat pain and this was experienced by 87% of 
patients at end RT. By 6-month post RT, 30% of patients still experienced throat pain. 
Fifty-five percent of patients had moderate/severe dysphagia by the end of RT. This 
decreased to 16 at 2-month post RT and further to 5% by 6-month post RT. A similar 
pattern is found for mouth dryness. Seventy-one percent of patients reported 
moderate/severe mouth dryness at end RT. Although the percentage declined during 
the recovery period in the subsequent months, there were still 45 % of patients 
reporting moderate/severe mouth dryness at 6-month post RT. 
• Appetite change at different time points is shown in Table 5.7. By the end of RT, 
89% patients had worse appetite when compared with that at pre RT, but 92% and 
97% patients, respectively, had improved appetite at 2-month post RT and 6-month 
post RT, compared with that at end RT. 
Over 90% of patients had problem with taste at end RT and 2-month post RT. 
Patients' taste scores of sweet, salty, bitter and sour taste qualities are shown in Table 
� 5.8 and Figure 5.12. The discrepancy among the number of responding patients for 
different taste categories at different time points was because some patients did not 
have the opportunity to test all taste qualities in their usual diet. The mean score 
shown at each time point was obtained from the patients who had given response at 
the respective time points. 
By the end of RT, the mean taste scores of all the four taste qualities were low, i.e. 
below 3, but started to increase after the completion of RT. At 2-month and 6-month 
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post RT, the scores of all taste qualities were significantly higher than those at end 
RT. A trend of progressive recovery was also evident, with the taste score of sweet, 
salty and bitter qualities at 6-month post RT being significantly higher than that at 
2-month post RT. The sour taste was an except in that, it did not show significant 
change between 2-month and 6-month post RT. 
Patients complained of exaggerated salty and sour taste at all three time points, 
especially in sour taste. Twenty-nine percent of patients reported exaggerated sour 
taste at 6-month post RT. 
Table 5.9 lists the food items most often mentioned as being difficult to eat and as 
• tasting abnormal after radiotherapy. Food with tough consistency, i.e. meat, and dry 
foods were listed as food items being most difficult to eat. Patients took juicy foods 
and fluids more frequently after the end of RT. High protein foods, i.e. meats, eggs 
and diary products, rank high in abnormal-tasting foods at end RT and the 
subsequent months. Table 5.10 shows the 5 main food items that were purposely 
avoided and 3 main food items that were purposely eaten more by the patients. 
Figure 5.14 shows that milk, vegetables and fish were the food items they tended to 
“ , e a t more after RT, whereas Figure 5.13 lists the main food items patients purposely 
avoided, which included fried foods, chicken, duck/goose, preserved foods and 
shrimp/crab/lobster. 
Table 5.11 shows the main reasons for eating less after RT as perceived by the 
patients. Taste alteration was one of the main reasons shown at all three time points 
after RT. At end RT, throat pain was the most common reported problem (53% of 
patients). However, at 2-month and 6-month post RT, it was loss of appetite and taste 
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alteration which were the main reason for eating less. Apart from these reasons, 
dysphagia, mouth dryness, less food choice and a feeling of easily getting full were 
also mentioned by patients at certain time points. 
5.2.3.2 Detailed profile of symptoms during RT 
The profile of change of radiotherapy-related symptoms during the early part (Week 
2 and Week 4) of radiotherapy was further studied in 11 patients,. Figure 5.15-5.17 
showed that after the first 2 weeks of RT, all patients (11/11) were already aware of 
throat pain, and the number decreased to 8 patients after another 2 weeks of RT and 
continued to decline by the end of RT. The number of patients experiencing 
moderate/severe dysphagia peaked after the first 4 weeks of RT. The number of 
‘ patients who suffered moderate/severe mouth dryness also peaked after the first 4 
weeks of RT. 
Figure 5.18 shows the time course change of appetite during RT. There was a 
progressive increase in the number of patients affected. By the end of RT, 10 out of 
11 patients had appetite loss. 
� The taste scores changes during RT are shown in Figure 5.19. Taste scores of all 
qualities were affected from the early part of RT. After the first 2 weeks of RT, 9 of 
11 patients were already aware of taste alteration, whereas after 4 weeks of RT, all 
patients experienced taste change. 
5.2.4 The profile of cytokines during and after completion of RT 
To gain insight of the potential role of cytokines in mediating weight changes, serial 
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serum TNF-a and serum leptin assessment were performed on nine patients at pre 
RT (To), 2-week after commencement of RT (Ta), 4-week after commencement of 
RT (Tb), end RT (Ti), and 2-month post RT (T2). 
5.2.4.1 SerumTNF-a 
Serum TNF-a showed a decrease at 2 weeks after commencing RT (Figure 5.20 and 
5.21). Figure 5.22.shows that there were no obvious relation between the trends of 
percentage change of serum TNF level and percentage change of either body fat or 
lean body mass. This lack of relation is also apparent when individual figures of 
percentage change in BMR and serum TNF are examined (Figure 5.23). 
‘5.2.5.2 Serum leptin 
Figure 5.24 and 5.25.show that there was no remarkable trend of serum leptin level 
during and after end RT. Individual figures (Figure 5.26) generally showed changes 
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Table 5.1 Bodyweight, BMI, body composition and weight loss in NPC patients, n=38 (mean±SD) 
To ^ J j Ti T3 
Bodyweight(kg) 63.3±11.4 56.5±10.9- 55.7+10.3- 55.5+9.5-
BMI(kg/m2) 24.2±3.9 21.5±3.7- 21.3±3.4- 21.16±3.2-
Body fat(kg) 15.1±4.9 12.4±4.7- 10.9±3.8-'^  10.4±3.5-' 
% body fat 23.6±6.0 21.5±6.6- 19.2±5.0-’’4 18.1±5.2-'^  
Lean mass(kg) 46.2±8.3 42.1 ±7.8-’ 42.8±7.6--^  43.3±7.5工"^  
% lean mass 73.5±5.9 74.9+6.3^  77.2±4.8-' ‘‘ 78.1±4.7-'^  
« 
% of patients with 
weight loss 
^ 5 % 86.8(33) 86.8(33) 81.6(31) 
乏 1 0 % 5 2 . 6 ( 2 0 ) 6 5 . 8 ( 2 5 ) 6 3 . 2 ( 2 4 ) 
% of patients 
(compared to Ti) 
with weight loss 57.9(22) 50.0(19) 
” with weight gain 42.1(16) 50.0(19) 
Brackets () indicate no. of patients 
1 p<0.05, Vo.OOl vs. To.'"V multiple comparison. p^<0.05, VO.OI, 5p<0.001 vs. T,. by 
multiple comparisons. 
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Table 5.2 Body weight and body composition change in N P C 
patients by the end ofRT, n=38 (mean±SD) 
AtT, 
(Change with 
reference to To) 
% change of bodyweight -10.8±5.9 
Bodyweight change (kg) -6.9+4.0 
% change of lean body mass -8.9±5.5 
Lean body mass change (kg) -4.2土2.9 
% change of body fat -19.0±13.2 
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Table 5.3 Anthropometric measures between NPC patients who increased (increase) and those who 
decreased (decrease) body weight from T, to T3. 
T ^ Ti 
Body weight 
change from Ti Decrease Increase p Decrease Increase p 
to T3 
Bodyweight 68.8 57.9 0.002 62.2 50.8 0.001 
(kg) 
BMI (kgW) 25.8 22.6 0.008 23.3 19.8 0.002 
Percent body 26.3 20.8 0.004 24.5 18.5 0.03 
fat (0/0) 
Percent lean 71.3 75.8 0.017 72.1 77.7 0.004 
% 
body mass (%) 
V-
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Table 5.4 Calorie intake and estimated energy requirement in N P C patients, n=38 (mean±SD) 
To T, T2 Ta 
Calorie intake 
•daily(kcal) 1857士411 1168±549"^ 1960±544^ 1847±38l'' 
•% of R D A 77.0+14.9 48.9±23.5^ 81.6±21.3"^  77.3±16.8'^  
•o/o of patients with 36.8 10.5 47.4 39.5 
intake >80% of R D A * 
•o/oofBMRxl.5 88.6±18.7 64.5+31.4" 107.7±25.8^103.7±21.2''' 
•% of patients with 63.2 26.3 84.2 94.7 
intake >80% of 
BMRxl.5 
Carbohydrate 
•intake (g) 248±60 170±73^ 252±69"^  233土60.8"^  
. • % of kcal 53.9±8.7 60.7+11.7^ 52.2±7.6^ 50.5+8.9" 
Protein 
• intake (g) 83±29 44±2f SSiSS"^  S2±2l^ 
• % of kcal 17.8±4.0 14.6±4.4^  17.2±3.44 17.9±3.6^  
• % of R D A * 109.4 士35.4 58.5±35.7^ 112.0±42.4^ 108.0±26.6'^  
• % of cancer patient 98.8±34.0 61.0±40.03 114.1±40.0^'112.3±34.0'' 
requirement 
(1.35g/kg)… 
• per bdwt (g/kg) 1.33 士0.46 0.82±0.54^ 1.54+0.54^'' 1.52±0.46^ 
. F a t 
•intake (g) 59.9+19.9 35.1+24.6^ 66.8123.9" 63.7士 18.26 
• % of kcal 28.8±5.9 24.9±9.7 30.4±5.5' 31.1+6.1' 
.Calorie intake/bdwt 
(kcal/kg) 29.9±7.1 21.7±12.1^ 35.8±9.6-' 34.1±8.2' 
• 1988 China RDA 
* * (Lindsey et al. 1994) 
• ••(Curtin University of Technology 1999) 
ip<0.05 vs. To； 2p<0.01，3p<0.001 vs. Tq/'^ by multiple comparisons. 
4p<0.05 vs. To； 5p<0.01，6p<0.001 vs. Ti/'^by multiple comparisons. 
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Table 5.5 Basal metabolic rate (BMR) and total energy expenditure (TEE) for NPC patients, n=38 
(mean±SD) 
To Ti I2 T3 
B M R (kcal) 1406±204 1230+190" 1220+195' 1199+168" 
BMR/bodyweight 
(kcal/kg) 22.5±2.6 22.1±2.9 22.3±3.0 22.0±2.5 
BMR/lean body 
mass (kcal/kg) 30.7±3.0 30.0±3.4 28.7±3.6^  28.0±2.4^ 
TEE (kcal) 2494±729 1769±430- 2012±448- '' 2043±428-' ^  






Chapter 5 Results 
Table 5.6 Energy balance for NPC patients, n=38 (mean士SD) 
To ^ T2 T3 
Calorie intake 1857±411^ 1168±549^ 1960±544 1847±38l' 
TEE (kcal) 2494+729 1769±430 2012±448 2043士428 
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Table 5.7 Appetite change in NPC patients after the end of RT (n=38). 
End RT 2 mth post 6 mth post 
^ RT 
% of patients having 
appetite loss compared 89 58 37 
with Pre RT 
% of patients having 
appetite increase compared --- 92 97 
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Table 5.8 Taste alteration and taste response in N P C patients after the end of RT (n=38). 
End RT 2-mth post 6-mth post 
RT RT 
% of taste 
alteration 97 92 79 
SWEET 
•Total no. of patients 
response 38 38 38 
•No. of response of 
"oversensitive" [percent] 0 1[2] 2[5] 
•Mean taste score (±SD) 1.71(±2.54) 4.09(±3.12) 6.68(±3.12) 
SALTY 
•Total no. of patients 
response 33 34 34 
•No. of response of 
"oversensitive" [percent] 2 [6] 3[8] 4[11] 
•Mean taste score (±SD) 2.44(±3.53) 4.75(±3.41) 7.16(±3.20) 
BITTER 
•Total no. of patients 
response 24 26 34 
•no. of response of 
"oversensitive" 0 0 0 
•Mean taste score (+SD) 2.23(±3.65) 5.25(±4.02) 7.16(±3.15) 
V 
SOUR 
•Total no. of patients 
response 19 3 3 3 4 
•No. of response of 
"oversensitive" [percent] 3 [16] 10[30] 12 [35] 
•Mean taste score (±SD) 2.16(士3.97) 4.89(±3.84) 6.59(±3.48) 
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Table 5.9 Eating habits in NPC patients after the end of RT (n=38). 
End RT 2 mth post 6 mth post 
RT RT 
Difficult-to-eat foods 
/Tough foods 22(58) 22(58) 16(42) 
/Hard/fried foods 6(16) 12(32) 16(42) 
/Fruits and vegetables 9(24) 8(21) 2(5) 
/Dry foods—bread, cereals24(63) 34(89) 33(87) 
/Citrus fruits, juices 6(16) 4(11) 2(5) 
/Sweets 1(3) 2(5) 1(3) 
Abnormal tasting foods 
/High protein foods* 26(68) 24(63) 20(53) 
/Fruits and Vegetables 20(53) 25(66) 15(39) 
• /Sweets 0(0) 6(16) 3(8) 
/Breads and cereals 21(55) 21(55) 11(29) 
/Coffee, tea 3(8) 15(39) 13(34) 
Brackets () indicate the percentage of patients' response. Remaining patients did not complain of 
difficulty in eating or abnormal tasting food. 
*High protein foods include milk, egg and meat. 
V 
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Table 5.10 Eating habit in NPC patients after the end of RT (n=38). 
End RT 2 mth post 6 mth post 
RT RT 
5 main food items 
that are purposely NOT eaten 
•Fried foods ^(68) ^(53) ^(45) 
•Meat (all kinds) ^(32) - -
•Chicken - ^(34) ^(32) 
•Duck/goose ^(26) ^(47) ^(42) 
•Preserved foods* ^(50) Z(58) ^(66) 
•Seafood (all kinds) ^(47) Z(39) -
•Shrimp/Crab/Lobster - Z(34) / (37) 
•Fruits Z(26) - „ 
•Hot and spicy foods Z(26) -- --
Other food items reported in these 3 time-points: beef, egg, soy products, rice, coffee/tea, 
soft drinks and alcoholic drinks. 
3 main food items 
that are purposely eaten more 
•Milk Z(42) Z(21) / (16) 
•Breads and cereals Z(29) ~ -
•Vegetables - ^(42) Z(53) 
•Rice/Congee ^(32) -
•Fish -- Z(26) Z(26) 
� Other food items reported in these 3 time-points: fruits, soups, tonic/bird nest, fruits juices, 
soymilk, pork, eggs. 
Blankets () indicate the percentage of patients' response. Remaining patients did not mention their 
• preference on that kind of food. 
“--“does not represent “ zero" response. Percentages are not shown because they are not the 5 or 3 
main food groups reported at that particular time point. 
*Preserved food includes preserved vegetables and fish. 
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Table 5.11 Main reasons for eating less reported by NPC patients (n=38) [ascending order]. 
End RT 2 mth post 6 mth post 
BJ BJ 
•Throat pain (53%) "No appetite (21 %) •Taste problem (21 %) 
•Taste problem(29%) •Others (18%) •Mouth dryness (16%) 
•Dysphagia (26%) •Taste problem (16%) "Less food choice (16%) 
•No appetite (26%) •Easily feel full (11%) 
"Others" includes teeth problem, stuffy nose, self control (for losing weight), tongue 
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Figure 5.a Serial body weight in NPC patients (n=386) 
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Figure 5.b Serial percentage body weight change in NPC patients 
(n=386) 
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Figure 5.c Serial body weight in NPC patients with complete 
time series (n=226) 
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Figure 5.d Serial percentage body weight change in NPC patients 
with complete time series (n=226) 
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Figure 5.e Comparison of freedom of Distant Metastases of patients with 
weight loss > or < 10 % 
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Figure 5.f Comparison of freedom of local or regional failure of patients with 
weight loss >or < 10 % 
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Figure 5.1 Body weight in NPC patients during 
RT (n=11) 
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Figure 5.2 Percentage body weight change in NPC patients during RT (n=11) 
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Figure 5.3 Median percentage body composition change during RT (n=11) 
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Figure 5.4 Calorie intake in NPC patients during RT (n=11) 
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Figure 5.5 Median calorie intake per kg body weight in NPC patients during RT . 
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Figure 5.6 Basal metabolic rate in NPC patients during RT (n=11) 
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Figure 5.7 Median BMR per kg lean body mass in NPC patients during RT 
(n=11) 
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Figure 5.8 Total energy expenditure (TEE) in NPC patients during RT (n=11) 
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Figure 5.10 
Throat pain in NPC patients after the end of radiation therapy 
(n=38) 
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Figure 5.10 




80 -[ I 
70 0) * w fin > 
§ 叫 c - g — … • n o & m i l d §• 50 W , . 
^ 40 ^ ^ ^ . : Q moderate 
。丨 r三 . i = ' 
Q I " f t i j l ‘ 1 ' • ‘ fe^ 诚 I 




Chapter 5 Results 
Figure 5.10 
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Figure 5.12 Taste score in NPC patients after the end of radiation therapy (n=38) 
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e) Score of bitter taste g) Score of sour taste 
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Figure 5.13 Main food items that are purposely not eaten by NPC patients after RT 
(•Preserved foods include preserved/salted fish and vegetables) 
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(Main food items that are purposely not eaten by NPC patients at different time points) 
c) At 6 mth post RT 
Preserved 
foods* 
/ ^ ^ ^ ^ ^ 30% 
A . 
Shrimp/Crab/Lo y：：：：；：：：^^  ^ ^ ^ ^ ^ ^ ^ ^ 
bster ：：：：：：：；；：：：：few 
17% I�:丨出出 





Chapter 5 Results 
Figure 5.14 Main food items that are purposely eaten more by NPC patients after RT 
(# Milk includes fresh milk, milk powder and Ensure) 
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c) At 6 mth post RT 
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Figure 5.15 Throat pain iQ NPC patients during and after the end of 
radiation therapy (n=11) 
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Figure 5.16 Dysphagia jn NPC patients during and after the end of 
radiation therapy (n=11) 
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Figure 5.17 Mouth dryness in NPC patients during and after 
radiation therapy (n=11) 
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Figure 5.18 Appetite change in NPC patients during and after the 
end of radiation therapy (n=11) 
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Figure 5.19 Taste score in NPC patients during radiation therapy 
Each line represents individual patient 
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Figure 5.20 Serum TNF level in NPC patients during and after end 
RT(n=9) 
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Figure 5.21 Percentage change of serum TNF level during and after 
end RT (n=6) 
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Figure 5.22 Percentage change of body composition and serum TNF level (Patient 
a-f) 
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Figure 5.23 Percentage change of BMR and serum TNF (Patient a-f) 
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Figure 5.24 Serum leptin level in NPC patients during and after 
end RT (n=9) 
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Figure 5.25 Percentage change of serum leptin level during and after 
RT (n=6) 
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Figure 5.26 Percentage change of body fat mass and serum leptin level 
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6.1 RETROSPECTIVE STUDY 
There were very few studies in the literature that addressed the long-term impact of 
short-term weight loss during oncological therapy on long-term survival. The studies 
usually involved only a relatively small sample size. The present retrospective study 
capitalized on the opportunity to study a large sample size of one cancer treated 
under uniform protocols. A large sample size is essential in order that the impact of 
known prognostic factors such as cancer stage, age and gender and treatment details 
can be taken into account of in multivariate analysis. It is reassuring that despite the 
significant degree of weight loss during and after radiotherapy, there was no evidence 
of a deleterious effect on subsequent cancer recurrence and survival. The conclusion 
is in concordance with previous studies involving small sample sizes. Other studies 
* had shown that despite the success of gastrostomy tubes in minimizing weight loss 
during oncological therapy for head and neck cancers, there was no improvement in 
survival in the tube-fed patient group. In Pezner's study (Pezner et al. 1987) on Stage 
III and IV squamous cell carcinoma of the head and neck, survival was not affected 
by tube feeding. On the other hand, there were also studies that suggested a possible 
adverse effect of weight loss on survival. Enig et al (Enig et al. 1986) studied 30 
patients with local bladder tumors before and during radiotherapy. When patients 
, were grouped according to age, tumour category, histologic grade, treatment, 
weight/height index and changes in weight and anthropometrical parameters, it was 
found that the weight/height index and changes in weight during 4 weeks of 
radiotherapy had significant influence on survival. In van Bokhorst-de van der 
Schuer's study (van Bokhorst-De van et al. 1999) on head and neck cancer patients 
treated by surgery and post-op radiotherapy, preoperative weight loss of >5% was 
found to have a negative effect on the 3-year survival probability of male patients. 
However, the sample size in these studies were relatively small, and the confounding 
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effect of different disease and treatment-related variables cannot be excluded. 
Although, weight change was not a prognostic factor on cancer recurrence and 
cancer survival in our patients, it is still important to explore the determinants of 
severe weight loss to assess the prospect of interventions that can improve the 
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6.2 PROSPECTIVE STUDY 
6.2.1 The magnitude of the problem 
In our group of NPC patients, 87% had >=5% weight loss by the end of a 6-8 week 
course of radiation therapy, and 53% had >=10% weight loss. The proportion of 
our patients with >10% weight loss was much higher than the head and neck cancer 
patients undergoing radiotherapy studied by Donaldson et al. (Donaldson & Lenon 
1979). In that study, only 9% of them experienced >10% weight loss. The mean 
percentage weight loss in our study was 10.8%,which was higher than the mean 
weight loss of 6.4% of a group of early laryngeal carcinoma patients treated by 
radiotherapy as reported by Collins et al. (Collins et al. 1999). The large magnitude 
of weight loss during RT in NPC patients, compared to other head and neck cancers, 
‘ may be related to the relatively large radiation fields used for this cancer, which 
covered both a long length of upper food passage mucosa and also the salivary 
glands. In treatment of larynx cancer, the salivary glands are seldom irradiated. 
6.2.2 The potential determinants of weight loss 
Conceptually, weight loss is due to an excessive expenditure, a reduction in intake, 
and/or a wasting effect due to the cancer. The reduction in intake can be due to the 
，， effect of the cancer or due to the effects of treatment. Cancer wasting is considered 
unlikely to be an important explanation for the weight loss in our patients due to 
several considerations. Firstly, wasting is usually associated with cancer in a 
disseminated state and not a localized state. All our patients had cancer localized to 
the nasopharynx and neck region and none had distant metastasis. Secondary, the 
preliminary observations on the change in cytokines levels do not suggest that weight 
loss would occur. Thus it is relevant to focus on the factors related to energy 
expenditure and calorie intake and examine them in relation to weight change. 
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6.2.3 Is weight loss due to the cancer or due to its treatment? 
Before radiotherapy, <10 % of patients had BMI in the underweight range (BMI < 
18.5 kg/m^). This suggests that NPC by itself is very unlikely to lead to weight loss, 
in contrast to the situation reported for some other cancer types such as lung and 
pancreatic cancer. This is compatible with the clinical characteristic of NPC in that 
NPC is seldom associated with distant metastases at presentation and the tumor itself 
does not obstruct the food passage. In fact, 66 % of the patients presented with a 
BMI > 22.9 kg/m^. These data suggested that over 90% of patients were of good or 
even over nutrition before the commencing of radiation therapy. It is of interest to 
note a similarly low incidence of undernutrition in a report on head and neck cancer 
‘ patients by Collins et al. (Collins et al. 1999) where 13 % had undernutrition and, 
84% had good nutrition at presentation. Therefore, the body weight loss that 
occurred in our patients by the end of radiation therapy was largely due to the 
radiotherapy treatment itself. 
6.2.4 Is the weight loss influenced by pre-treatment factors, i.e.anthropometricai 
data? 
�， First of all, we found that none of the pretreatment factors were predictive for the 
weight loss by the end of RT. These findings are in concondance with studies by 
other investigators (Collins et al. 1999; Johnston et al. 1982). 
In our study, there was no difference in the pre-treatment BMI of the group of 
patients sustaining >= 5% weight loss and <5% weight loss after therapy. This is in 
concordance with the findings in the study of Johnston et al. which showed that 
pretreatment nutritional status and anthropometic measurements were not predictive 
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of weight loss during radiation therapy (Johnston et al. 1982). And the study by 
Collins et al. which showed that BMI of the head and neck patients at presentation 
was not predictive of weight loss during radiotherapy (Collins et al. 1999). 
6.2.5 Is the pattern weight loss compatible with the model of calorie-protein 
malnutrition, similar to a starvation state? 
In our NPC patients, the body weight and composition change during and after 
completion of radiotherapy was compatible with that seen in starvation and injury 
(Collin 2001), where the injury was caused by radiation therapy. In starvation model, 
a decreased in metabolic rate is noted, this can be shown in our patients than the 
basal metabolic rate after the end of RT was significantly lower that the pre treatment 
* level. However, the features of slow loss of body weight in the starvation model, 
was not replicated in our patients who lost >10 % of body weight loss within 6-8 
weeks of RT treatment which was quite a short period of time. This quick loss of 
body weight, with preferential loss of body fat rather than lean body mass resemble 
the characteristic of injury, which typically cause a rapid loss of body weight with 80 
% from fat stores, the remainder from body protein. During the post-RT recovery 
period, at 2-month and 6-month post end of RT, lean body mass of our patients 
, increased while body fat mass continued to fall. This concurs with the study by Cohn 
et al. (Cohn et al. 1981) that cancer patients with weight loss had lost mainly body 
fat. It also concurs with the findings in the animal study by Harris (Harris et al. 1986) 
which showed that there was regaining of body protein earlier than body fat in 
starved rats. Clinically, the model of weight loss is often complicated, as patients 
seldom fall simply into one category or the other, patients can be injured after a 
period of undernutrition, or underfed for some time after an injury (Collin 2001). In 
our patients，progressive and sustained injury to the upper food passage occurred 
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over a 2-month duration, which caused concurrent impairment of nutritional intake. 
It is thus shares the characteristics of both the starvation and injury model. 
6.2.6 Is the weight loss due to increased energy expenditure? 
In our patients, there is no evidence of increase of BMR during and at the end of 
radiation therapy, on the contrary, there was apparent decrease in BMR after RT 
which can be explained by the fact that BMR is directly proportional to body weight 
(National Research Council 1989). When BMR was controlled for bodyweight, no 
significant decrease in BMR/kg bodyweight was found by the end of treatment and 
this remained at a steady level, during the recovery period. This is similar to the 
findings in the study of Macqueen et al (Macqueen & Frost 1998) on head and neck 
• patients receiving RT, which demonstrated a decrease in BMR after radiotherapy. 
There is also no evidence of elevated TEE during RT. On the contrary, the patients' 
TEE was at the highest before the start ofRT and was at the lowest at the end ofRT. 
The lower TEE can be explained by reduced physical activity due to discomfort 
associated with radiotherapy, such as radiation sickness, mucositis, and dry mouth, 
and the poor nutritional status. 
Therefore, there is no evidence in increased energy expenditure affecting weight loss 
in our NPC patients. 
It is of interest to note in other cancer model, such as lung cancer, a decrease in REE 
may occur after the tumor removal (Luketich et al. 1990) (Fredrix et al. 1997). 
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6.2.7 Is the weight loss due to reduced calorie intake? 
The calorie intake before RT was essentially normal in our patients. The patients' 
average calorie intake met 77% of recommended dietary allowances (RDA) of China. 
The energy intake was 1.33 times of BMR. This is largely similar to the pre-therapy 
energy intake of 1.43 times and 1.19 times of BMR in head and neck cancer patients 
reported by other investigators (Enig et al. 1985). There was a marked reduction of 
calorie intake to sub-optimal level at completion of radiotherapy, the intakes of our 
NPC patients only met 49% of RDA, which was the lowest among the four time 
points, indicating severe malnourishment. Even when the energy requirement was 
calculated by BMR x 1.5 (Lindsey et al. 1994), patients only met 64.5% of the 
energy requirement at end RT. Similar findings of decrease in calorie intake at 
‘ completion of RT were also reported in groups of head and neck cancer patients 
(Chencharick & Mossman 1983; Macqueen & Frost 1998). And we found that 
percentage of body weight loss at end RT was correlated with the percentage change 
of calorie intake during RT (r=0.361). This implies that the larger the percentage 
decrease in calorie intake during RT, the greater the tendency for the patients to lose 
weight. Therefore, decrease in calorie intake during RT plays an important role in the 
body weight change. 
6.2.8 Is weight loss during radiotherapy due to negative energy balance? 
In our patients, there was a trend of correlation between weight loss and energy 
deficit at the beginning and at the end of radiotherapy, which did not reach statistical 
significance. Negative energy balance, i.e. energy intake < total energy expenditure， 
nevertheless, was appreciable by the end of RT where severe weight loss had been 
sustained. This implies that negative energy balance is likely to contribute at least in 
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part to the body weight change during RT (Nelson et al. 1994). Another possible 
cause for the weight loss is the effect of cytokines which may be activated by 
radiation or inflammation of the upper food passage (Costelli et al. 1993; 
Tocco-Bradley et al. 1987). Although the preliminary investigation on the alterations 
in the levels of two cytokines did not show changes that can readily explain a 
wasting effect, the mediating effect of other cytokines could not be excluded. 
The observation of an apparent negative energy balance before radiotherapy was 
similar to the findings in Lindsey study (Lindsey et al. 1994), where the mean calorie 
intake of cancer patients receiving RT only met 70% of energy requirement at the 
beginning of RT. As no pretreatment weight loss was found in our patients, there may 
. be an overestimation of total energy expenditure by physical activity questionnaire, 
which was subject to inaccuracies on the individual assessment level (Liu et al. 
2001). 
6.2.9 What causes reduced calorie intake: Are radiotherapy-induced symptoms 
contributive? 
Unlike other studies, which showed a proportion of head and neck patients were 
、， subjectively aware of mouth dryness prior to radiation therapy (Chencharick & 
Mossman 1983), our patients did not have complaint of mouth dryness, taste change 
or dysphagia prior to the radiation therapy. At the completion of RT almost all of 
. our patients experienced multiple symptoms induced by RT, including throat pain, 
dysphagia, mouth dryness and alteration in taste perception. Most patients suffered 
from moderate to severe degree of the above symptoms by the end of RT. The 
severity of symptoms also paralleled the decrease in calorie intake since the early 
part of RT and maximal at end RT, partly recover during 6 months post end RT. 
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Figure 6.19 shows the taste scores of patients continued to decline along the course 
of treatment. Sweet and salty qualities show more obvious trends. This is 
compatible with the radiotherapy port coverage in our patients, which includes a 
significant portion of the dorsal surface of the mid and posterior part of the tongue. 
The mechanism of such alteration was suggested to be radiation-induced damage to 
the microvilli of the taste cells, or their surface (Donaldson & Lenon 1979). The 
present study shows that subjective impairment of taste was already evident as early 
as the second week of a 6-8 week course of radiotherapy. (Mossman et al. 1979). 
A wide range of the time required for recovery of taste perception in head and neck 
‘ patients after radiation therapy have been reported, from a few months to a year after 
radiotherapy (Darbinian & Coulston 1990). Our patients suffered from severe 
hypogeusia (as shown by the low taste perception score in table 5.8) and dysgeusia 
by the end of RT where minimum calorie intake occurred. Nearly one-third of our 
patients had reported that taste problem was a factor that led them to eat less (Table 
5.11). However, about half of them had their taste qualities greatly improved at 
2-month post RT, alongside with the improvement in calorie intake. The discrepancy 
�， between recovery of calorie intake and recovery of taste perception might be 
explained by patients' awareness of malnutrition after the end of RT resulting in an 
active effort to maximize their energy intake despite the appetite loss which was 
found in half of the patients by 2 months post RT. For sweet and salty qualities, 10 
out of 38 (26%) and 15 out of 38 (39%) patients had completely recovered (score 10) 
at 6-month post RT. Another study showed some irradiated patients had recovery of 
sweet and sour qualities after 7 weeks of treatment, whereas no recovery of salt and 
bitter qualities was found within the study period (Mossman et al. 1979)，and some 
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patients may never completely recover their taste (Mossman et al. 1982). In the 
present study, only a portion of patients had completely recovered all taste qualities 
at 6-month post RT. A longer period of time, i.e. at least after a year, may be needed 
for total recovery of taste in our patients. This could be confirmed with a prospective 
study, which spanning over this time period. Abnormal taste with high protein foods, 
i.e. meats, egg and diary products, was common at and after the end RT (Table 6.9). 
Similar finding was also shown in the study by Chencharick et al. (Chencharick & 
Mossman 1983), and may be a consequence of altered salty and bitter taste qualities 
Administration of oral zinc sulphate may correct disorders of taste in some radiation 
therapy patients (Mossman & Henkin 1978). In our patient group, they tended not to 
try sour food, which was noted to be too irritating. 
« 
It had been reported that during a 6-8 week course of curative radiotherapy of 60 Gy 
or above, salivary function was observed to decline by the first week of treatment, 
with continued decrease throughout the period of radiation exposure (Chencharick & 
Mossman 1983; Mossman et al. 1982). By the end of therapy, many patients have 
little or no saliva (Mossman & Henkin 1978). Although we have not measured 
patients' salivary secretion, our observations on patients' subjective awareness of 
, mouth dryness by the end of radiation therapy concur with these findings. The 
severity of mouth dryness was the highest at the end of radiotherapy. It has been 
suggested that severe mouth dryness, which creates chewing and swallowing 
difficulties, lead to depressed oral intake. Patients who had an irradiation-induced 
low saliva secretion rate ate less than control group (Backstrom et al. 1995). 
However, our result does not show any significant correlation between the degree of 
mouth dryness and calorie intake. This might be explained by the observation that 
juicy and fluid food items such as milk were taken, which contribute to appreciable 
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calorie intake. Radiation therapy has been shown to induce early and persistent 
impairment of salivary gland excretion in several studies (Backstrom et al. 1995; 
Mossman & Henkin 1978). Another study showed that in some patients whose 
radiation-induced dysfunction in salivary secretion never completely resolve 
(Mossman et al. 1982), partial recovery of gland function had been observed to occur 
as early as 2 to 6-month after the end of RT (Darbinian & Coulston 1990). Our 
findings show, at 6-month post RT, there was still 45% patients who experienced 
moderate/severe dry mouth (Figure 6.11), which was much more frequent than 
dysphagia. 
All the symptoms described above are the most severe at the end of RT. The severity 
• of symptoms paralleled the decrease in calorie intake since the early part of RT and 
maximal at end RT, partly recover during 6 months post end RT. Reduction in 
calorie intake is closely related to multiple radiotherapy-induced symptoms in the 
head and neck region. 
6.2.10 What are the observations on and implications of cytokine changes? 
TNF-a is a cytokine with potential role in mediating weight change through 
� . interaction with lipolysis (Elbom et al. 1993; Orban et al. 1999) and muscle protein 
degradation (Costelli et al. 1993; Llovera et al. 1993). Studies have shown that 
TNF-a is elevated in NPC patients. Wang et al (Cui et al. 2001) has detected the 
level of TNF-a in nasopharyngeal secretion of NPC patients was higher than that of 
healthy controls. Yadav, M. (Yadav 1991) also demonstrated that the majority of 
NPC patients had serum TNF-a level of > 10 pg/mL whereas that of the control 
subject was not detectable. In our group of NPC patients, the serum TNF-a level was 
rather low at baseline before the start of radiotherapy, ranging from 1-5 pg/mL. This 
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is quite similar to the findings in a study on a group of breast cancer patients, where 
the TNF-a level ranged from 0-9 pg/mL (Geinitz et al. 2001). The TNF-a level in 
our patients fluctuated during the course of radiotherapy, and by the end of 
radiotherapy, two patients had decreased TNF-a level while 4 patients had increased 
TNF-a level. Such observation is in discordance to that of Kowalczuk et al. 
(Kowalczuk et al. 2001) who found a significant decrease in serum TNF 
concentration in cancer patients after radio and chemotherapy. On the other hand, 
Geinitz et al (Geinitz et al. 2001) did not find any significant change in TNF-a level 
during and after RT in breast cancer patients. The Author suggested that the death of 
tumor cells during RT might lead to more activation of the cytokine system than 
irradiation of normal tissue. (Krueger & Toth 1994). The clinical status of patients 
• may also be a factor accounting for elevation of serum TNF-a (Langer et al. 2001; 
Tisdale 1997). 
Administration of TNF has been shown to result in inhibition of lipoprotein lipase 
which inhibits the formation of fat (Beutler & Cerami 1988). Correlation of TNF 
with lipolysis has also been reported (Elbom et al. 1993; Orban et al. 1999). Previous 
studies also reported that administration of TNF in animals could lead to muscle 
“ , protein degradation (Carbo et al. 2000; Llovera et al. 1993). Therefore, it is of 
interest to see if there is a relation between TNF-a level and the change in body 
composition in our patients. However, such a relation was not observed in our NPC 
patients, suggesting that weight loss in our patients during raditotherapy is very 
unlikely to be explained by changes in TNF-a level. The lack of relation between 
TNF-a level and weight change in cancer patients was also apparent in other studies, 
such as a study on cachectic cancer patients (Socher et al. 1988)，and in a study on 
radiotherapy-treated breast cancer patients (Geinitz et al. 2001). 
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Elevated resting energy expenditure has been shown to be related to with TNF-a in 
cystic fibrosis patients (Elbom et al. 1993) and lung cancer patients (Staal-van den 
Brekel et al. 1995). In the present study, among the six patients present with the 
changes of BMR and TNF-a level, no relationship between them can be shown. 
The median serum leptin level in our group of NPC patients before the start of 
radiotherapy was 2.119 ng/mL (ranged 0.659-12.768 ng/mL), whereas that by the 
end of RT was 2.509 ng/mL (ranged 0.416-10.976 ng/mL). The readings were quite 
similar to that reported for a group of weight losing colorectal cancer patients, which 
showed median leptin concentration of 4.0 ng/mL (ranged 0.9-12.7) in males and 3.2 
• ng/mL (ranged 1.4-39.7 ng/mL) in females (Moses et al. 2001). In our NPC patients, 
the serum leptin level generally showed a downward trend during radiotherapy which 
paralleled the change in body fat mass. Such observation is in concordance with that 
of the study done by Maguire, R.M.D. (Maguire 2002). In his group of weight stable 
cancer patients, leptin concentration was significantly correlated with the baseline 
body fat mass and with the changes of fat mass after 6 weeks. 
�， Leptin level has been suggested to be increased by proinflammatory cytokines in 
human, including. TNF (Zumbach et al. 1997) and IL-1 a (Janik et al. 1997). 
Mantzoros et al (Mantzoros et al. 1997) suggested that TNF-a system might play a 
role in regulating leptin level. Serum leptin level elevated on repeated TNF infusion 
in patients with solid tumor which then returned to baseline level within 24 hours 
(Zumbach et al. 1997). Moreover, serum leptin concentration in cancer patients 
increased after administration of IL-1 a . (Janik et al. 1997). These cytokines can 
increase the plasma levels of leptin, despite the decrease in food intake that would 
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normally suppress leptin expression (Finck et al. 1998). 
The preliminary observation study on these two cytokines suggest that they are 
unlikely to be an important mediator of body weight change. 
6.2.11 What determines the recovery of body weight during 6 months after end 
of radiotherapy? 
For the weight change that occur during the subsequent 6 months after the end of RT, 
calorie intake per kg bodyweight (r = 0.497) at end RT correlated with it. This 
suggests that dietary intervention at the time point where patients were severely 
‘ malnourished, i.e. near the end of RT，is likely to have an impact on the pace of 
recovery during the subsequent months.. 
Apart fi'om the correlation with calorie intake density, although by the end of RT, no 
component of energy expenditure was found to correlate with body weight loss,, by 
the 6 months after RT, we found that BMR per kg body weight at end of RT was 
predictive for the body weight alteration at 6 months post RT. This observation is in 
V, 
. concordance with the study of a group of unselected cancer patients by Bosaeus et al. 
(Bosaeus et al. 2001). It also demonstrated that REE per kg bodyweight was 
significantly related to body weight loss. We also found that TEE (r = - 0.413) and 
energy balance (r = 0.392) at end RT correlated with the weight change during 6 
months post end RT. This implies that patients with less total energy expenditure at 
end of RT had lesser tendency to loss weight at 6-month post end RT. 
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Therefore, apart from dietary intake, patients' totally energy expenditure should also 
be monitored, to make sure that patients' calorie intake can meet or over their energy 
expenditure to reach a positive energy balance at all time. The delayed recovery of 
body weight compared to recovery of calorie intake in the post-radiotherapy period 
strongly suggest that the calorie intake during the early post-radiotherapy period was 
not sufficient to replenish the deficit incurred during radiotherapy. 
6.2.12 Is the weight loss in the post RT recovery period due to negative energy 
balance? 
During the subsequent 6-month after radiotherapy, energy balance was achieved by 2 
months post end RT and a slight degree of negative energy balance was found by 
i 
6-month post end RT. The lack of a positive energy balance up to at least 6 months 
after radiotherapy thus well explains the lack of recovery of bodyweight in our 
patients after radiotherapy. In fact, the degree of continued weight loss during the 
early recovery period correlated significantly with the degree of negative energy 
balance soon after the end of RT. This implies the importance of establishing positive 
energy balance as early as near the completion of RT in order to achieve weight 
,„ recovery. Since our patients only met 50-80% of RDA of energy intake at that time 
fr 
point, there should be much room to increase their calorie intake to meet and 
maintain at least 100% of RDA value, in order to reverse the negative energy 
. balance. 
6.2.13 What are the implications on nutritional intervention? 
The present study has provided evidence of inadequate calorie intake during the 
weight loss period, and shows that there is no evidence of increased expenditure in 
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terms of TEE and BMR. This implies that enteral nutritional support is likely to 
have an impact on preventing weight loss during radiotherapy for NPC and in 
accelerating weight recovery in the post-radiotherapy period. Furthermore, there is 
evidence from other studies that the quality of life of patients can be improved with 
nutritional intervention. 
Malnutrition during radiotherapy treatment has been shown to be associated with 
more symptoms and inferior quality of life. Johnston et al. (Johnston et al. 1982) 
showed that oral pain, dysphagia, xerostomia and dysphagia associated with 
radiotherapy of head and neck cancer patients were more severe and longer lasting in 
the malnourished patients who experienced weight loss. Commencing nutritional 
‘ support in these patients may show improvement in their quality of life and 
nutritional status, especially when these patients are suffered from severe 
malnutrition (Nitenberg & Raynard 2000). 
In our patients, they had the lowest calorie intake by the end of RT. From the 
subjective report of the patients (Figure 5.18), they tended to eat less during RT. The 
reason for their appetite loss included a wide spectrum of radiation-induced side 
effect (Table 5.11). Because of swallowing difficulties, patients usually sip with 
water or soup when swallowing food. They tended to eat more carbohydrate food 
(Figure 5.14) at end RT with modification of texture. Rice is usually moistened with 
soup. Bread, biscuits or cakes are usually moistened in water or milk which helps in 
swallowing. If they could eat meat, they preferred meat with fat rather than lean meat, 
which the texture is harder. And minced meat is easier for them to swallow. Some 
patients purposely refrain from not eating some food items at end RT and during time 
after end RT. Those food items shown in Figure 5.13 were mainly regarded as "wet 
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and hot" in traditional Chinese diet. In traditional Chinese diet therapy, the "wet and 
hot" food items were suggested to be avoided in disease. Therefore, it is worth for 
giving more advice on modifying food consistency and texture to increase food 
intake for the patients. According to Bradford (Bradford 1990), pureed foods, such as 
thick soup, mashed potato and creamed wheat cereal; thick liquids, such as thinned 
plain yogurt; ground meats and vegetables can be a good choice for the patients with 
mild or moderate degree of dysphagia. 
Patients should be encouraged to eat a variety of food in amounts adequate to 
maintain or increase body weight. High-energy or high protein diet provided with 
adequate amount of vitamins and mineral is required to minimize weight loss, and 
• facilitate repair and regeneration of damaged tissues. Holmes, S. (Holmes 1997) 
suggests that a voluntary intake less than 80% of required amount indicates the need 
for nutritional support. Ravasco et al. (Ravasco, I 2003) assessed the quality of life 
and nutritional status in cancer patients referred for radiotherapy, including those 
with head and neck cancer patients，and had defined them as high risk group because 
of the expected RT- induced symptoms. They reported that, by the end of RT, the 
quality of life improvement in high risk group correlated with increased dietary 
, intake. These can be achieved in several ways. Additional milky drinks can be an 
option to increase nutrient intake in patients with normal functioning of GI tract. 
During the recovery period, patients shifted their diet pattern from the soft one to the 
normal one gradually. And their intake increased gradually and reached the pre RT 
level at 2- 6 month post RT. More than 90% of patients had calorie intake of >80% of 
BMR X 1.5 which can regard as adequate. However, the body weight from end RT to 
6 month post end RT tended to further decrease, although to a lesser extent. This 
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suggests that the end-of-RT time point is a critical one when the calorie and protein 
intake were the lowest, and the radiation-induced symptoms maximal . 
Intensification of nutritional support at this time point should have impact on 
subsequent weight recovery. 
Various studies had applied enteral or parenteral nutrition on surgical, chemotherapy 
or radiotherapy cancer patients with limited oral intake to see if patients' nutritional 
status or quality of life can be improved. 
Van der Schueren et al (van Bokhorst-De van et al. 2000) reported that enteral 
nutrition improved QOL of severely malnourished head and neck cancer patients in 
‘ the period preceding surgery. Apart from giving nutrition support during surgery, 
researchers have also found that recent weight loss of more than 10% prior to surgery 
appeared to be of great prognostic value in the occurrence of major postoperative 
complications. Therefore, findings suggest that preoperative nutrition may reduce 
postoperative complications in surgical head and neck cancer patients (van 
Bokhorst-de van der Schueren et al. 1997). Use of preoperative TPN has been 
applied in surgical gastrointestinal (Muller et al. 1982), abdominal and thoracic 
� (Anonymous 1991) cancer patients to see if less postoperative complications 
occurred. Mullen et al (Muller et al. 1982) showed that rates of postoperative wound 
infection, pneumonia, major complications, and mortality were generally lower in 
preoperative PN group of gastrointestinal cancer patients, which PN was supplied for 
10 days. However, differences were only significant for major complications and 
mortality. Another group of researchers (Anonymous 1991) found that the 
administration of TPN, ranged from 7-15days, had no benefit except in severely 
malnourished abdominal and thoracic cancer patients. Similar conclusion has been 
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found by Klein et al. (Klein et al. 1986)，no statistically significant benefit from TPN 
could be demonstrated in survival , tumor tolerance, tumor toxicity or tumor 
response in CT or RT patients. In a review of PN in CT cancer patients, use of PN 
was found to be associated with 4 times the increase risk of significant infection. It 
suggested the PN support may only be of benefit to severely malnourished patients 
(Anonymous 1989). 
For radiotherapy patients, Pezner et al (Pezner & Archambeau 1985) had reviewed 
that various nutritional support, including tube feeding and intravenous 
hyperalimentation, had been employed to limit weight loss and lessen intestinal RT 
side effect. As RT often limits oral intake and further impair patients' nutritional 
• status, it is suggested that nutritional support during preoperative RT might be able to 
lower the complication rate for malnourished patients, maintain body weight (Lees 
1997), stabilize quality of life (Senft et al. 1993) and even improve anthropometric 
and biochemical parameters in head and neck patients (Fietkau 1998). Bertrand et al. 
(Bertrand et al. 2002) has reported that preoperative EN reduced 10% of 
postoperative complications in head and neck patients with weight loss >10%. Daly 
et al. (Daly et al. 1984) reported that the tube fed patients had maintained mean 
mid-arm circumference and recovered mean serum albumin level after RT when 
興 
compared these with orally fed patients. Outpatient tube-feeding provided during RT 
also improved and maintained body weight and calorie intake compared with those 
patients with oral fed. Holmes S. (Holmes 1997) suggested that enteral nutrition is 
more preferable than parenteral nutrition for head and neck patients usually have 
normal GI function when their oral intake is inadequate. Enteral nutrition preserves 
intestinal function and promotes more efficient nutrient use than parenteral nutrition 
and causes fewer complications, because the stimulated gut mucosa has not atrophied 
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(Lees 1997). Enteral nutrition (EN) apparently is more safe than PN. It can be 
applied through nasogastric tubes or percutaneous endoscopic gastrostomy (PEG). 
Both methods had been shown to be equally effective at maintaining body weight in 
head and neck patients receiving radiotherapy (Lees 1997; Magne et al. 2001). But 
more studies reported that applying enteral feeding by PEG was effective in 
stabilizing nutritional status in these patients (Fietkau et al. 1991; Senft et al. 1993). 
These findings do show the importance of nutritional assessment and support in head 
and neck patients before, during and after the treatment period. Enteral feeding is 
more preferable than parenteral feeding in this patient group since they usually have 
normal GI tract. 
t 
6.2.14 Limitations and future studies 
The main limitation of this study is the lack of data on the quality of life of the 
patients. Since a period of severe but temporary weight loss has not been proven in 
this study to inversely affect long term survival from cancer, the potential 
improvement in quality of life by nutritional intervention is an important reason for 
for instituting nutritional intervention. With the lack of weight recovery by the end 
‘ of the study period, i.e. 6 months after radiotherapy, it is of interest to extend the 
study period to see if subsequent weight recovery would occur as predicted by the 
degree and duration of positive energy balance. To further investigate the 
hypothesis that the lack of weight recovery is due to a negative energy balance, it 
would be of interest to embark on a study comparing the effect of implementing and 
not implementing nutritional support during and after radiotherapy treatment on 
weight change. 
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Chapter 7 Conclusion 
1. In the prospective study on weight change during the radiotherapy period, it was 
found that weight loss was evident as early as the second week of radiotherapy and 
was the worst by the end of radiotherapy, with significantly greater percentage loss 
of body fat than that of lean body mass. Body weight did not return to pre-treatment 
level by 6 months after radiotherapy. In the retrospective study on 386 NPC patients, 
it was found that subsequent to the marked decline in body weight during 
radiotherapy, the body weight actually troughed at 3-6 months after radiotherapy. 
The time taken for recovery of body weight to pre-treatment level was variable and 
may take up to 4-5 years. 
2. Weight loss of 10% or more during radiotherapy is not a significant determinant of 
• cancer recurrence (local-regional recurrence, distant recurrence) or cancer-related 
death for nasopharynx cancer. 
3. The potential determinants of weight loss has been investigated, and it was found 
that 
(i) Weight loss was largely related to the radiotherapy treatment rather than the 
cancer. 
(ii) Weight loss during radiotherapy was not related to pre-treatment 
anthropometrical parameters. 
(iii) The observation of preferential loss of body fat compared to lean body mass, 
over a short duration of 2 months of radiotherapy, with reduced BMR, was 
compatible with a model of malnutrition characterized by a starvation element and an 
injury element. This is compatible with radiation-induced inflammation of the upper 
food passage causing reduced food intake and a period of sustained inflammation. 
(iv) There is no evidence of increased energy expenditure, in terms of BMR per 
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kg body weight, affecting weight loss. 
(V) There is no evidence of increase in TNF-a level and leptin level as 
mediating mechanisms of weight loss. 
(vi) The percentage of body weight loss at end of radiotherapy correlated with 
the percentage change of calorie intake during radiotherapy, suggesting that weight 
loss was primarily due to inadequate calorie intake. This, coupled with a lesser 
degree of reduction in energy expenditure, resulted in negative energy balance, 
implies that nutritional intervention during the radiotherapy period is likely to have 
impact. 
(vii) Reduction in calorie intake is closely related to multiple 
radiotherapy-induced symptoms including dry mouth, sore throat, dysphagia and 
‘ dysgeusia/ hypogeusia. 
(viii) Calorie intake per kg bodyweight, TEE, and energy balance at completion 
of radiotherapy all correlated with weight recovery during the 6-month period after 
radiotherapy. This suggests that dietary intervention aiming at enhancing 
nutritional intake density at completion of radiotherapy, when patients were severely 
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Appendix 
Department of Clinical Oncology 
The Chinese University of Hong Kong 
The Nutritional Study of Nasopharyngeal Carcinoma Patients 
Because of the changes in body metabolism and dietary habit after receiving 
radiotherapy, most patients will lose their weight. Study shows that their weight usually will 
not be resumed even with increased dietary intakes. Despite of this, Department of Clinical 
Oncology of the Chinese University of Hong Kong is going to conduct a study investigating 
the relationship between various factors that may lead to failure of gaining weight. The study 
will last for about 8 months. Within this period, clinical staff will examine the dietary habit, 
energy expenditure, body composition and nutritional maker of the participants. 
We will ask the participants to have following measurement: 
1. Dietary record Date: 
2. Physical activity questionnaire Date: 
3. Basal metabolic rate: 
Participants need to fast for 10 hours before the examination. During the examination, 
participants will lay on bed with normal breathing for 30 min. 
Date: 
4. Body composition ( fat mass & fat-free mass ): 
The measurement will be done by using X-Ray Bone Densitometer, during which 
participants will lay down for 8 min. Date: 
The study will be divided into 4 phases. It is proved that there is no side effect for all 
measurement mentioned above. The radiation level for the Dual Energy X-ray 
Absorptrometry is the same as the background radiation, therefore, it is harmless to the 
participants. Moreover, the study will not affect the original treatment that the participants 
have to receive. Should you have any inquiries or feel anything uncomfortable during the 
study period, please feel free to inform our clinical staff. 
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Department of Clinical Oncology 
The Chinese University of Hong Kong 
The Nutritional Study of Nasopharyngeal Carcinoma Patients 
Consent Form 
Name: Sex: Age: 
H.K.LD.No.: 
Contact phone no.: • 
Address: 
« 
I totally understand the aims, the methods and the consequences of this study 
and I understand this study will not affect the original treatment I am going to 
receive. 
« 
I， , agree to join The Nutritional 





Appendix 2 Consent form I (in Chinese) 
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‘ 2.日常活動問卷調查 檢查日期: 
3.量度基本代謝率(Basal M e t a b o l i c Ra t e ) : 
參加者需於檢查前 1 0小時停止飮食。檢查其間，參加者只 
需平臥於床上，保持正常呼吸。檢查時間約三十分鐘。 
檢查日期: 
4 .量度身體成分 ( B o d y Compos i t ion ) -脂肪比例、純體重等： 














參加者姓名： 性別 年齡 
身份証號碼： 1_ 
聯 絡 電 話 ： 




本人 — 同意參加這次 
《鼻咽癌病患者之營養狀況調查》。 




Appendix 3 Consent form II (in English) 
{ 
如 -
•r -•.•J： -、. ... ,. 、. 
.J 
C 
• • • ： 1 
• •、》 “ 
‘‘？. t V ’： . ? • - - » 
. . ‘ • 
* 
• I ‘ 
必‘ ..、•（.. ‘ 
；• • 
.t 
. . . ' • , . _ • . . 。 • 
-》• A% • ‘ •：' . ‘ , . ； 1* • -
• - • 
‘ ： 丨 . . . . 
f ) •： r：-, • • 
t 
� • - • -
.二 ‘••--, I '•<、：• 
• ； ] V.-' .> • I « 
• • ‘ ‘ . , 
^ … • • • . ‘ 
� - f t , - -r.-r . . 
‘ 、 - . . . . - … 、 ： 
‘ ‘ - V ‘ 196 , . . 
- ‘ 、 - .乂 -：： 
•  • . ../,:[: .:“>•、、；、 ....•‘ ..... . ‘ .. -..、_，".广.凡、 
Appendix 
Department of Clinical Oncology 
The Chinese University of Hong Kong 
The Nutritional Study of Nasopharyngeal Carcinoma Patients 
Because of the changes in body metabolism and dietary habit after receiving 
radiotherapy, most patients will lose their weight. Study shows that their weight usually will 
not be resumed even with increased dietary intakes. Despite of this, Department of Clinical 
Oncology of the Chinese University of Hong Kong is going to conduct a study investigating 
the relationship between various factors that may lead to failure of gaining weight. The study 
will last for about 8 months. Within this period, clinical staff will examine the dietary habit, 
energy expenditure, body composition and nutritional maker of the participants. 
We will ask the participants to have following measurement: 
1. Dietary record Date: 
2. Physical activity questionnaire Date: 
3. Basal metabolic rate: 
Participants need to fast for 10 hours before the examination. During the examination, 
participants will lay on bed with normal breathing for 30 min. 
Date: 
4. Body composition (fat mass & fat-free mass): 
The measurement will be done by using X-Ray Bone Densitometer, during which 
participants will lay down for 8 min. Date: 
5. Blood Test 
> 
Two nutritional makers, leptin and tumor neocrosis factor (TNF), in blood will be tested. 
Date: 
The study will be divided into 7 to 8 phases. It is proved that there is no side effect for 
all measurement mentioned above. The radiation level for the Dual Energy X-ray 
Absorptrometry is the same as the background radiation, therefore, it is harmless to the 
participants. Moreover, the study will not affect the original treatment that the participants 
have to receive. Should you have any inquiries or feel anything uncomfortable during the 
study period, please feel free to inform our clinical staff. 
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Department of Clinical Oncology 
The Chinese University of Hong Kong 
The Nutritional Study of Nasopharyngeal Carcinoma Patients 
Consent Form 
Name: Sex: Age: 
H.K.I.D.N0.: 
Contact phone no.: • 
Address: 
« 
I totally understand the aims, the methods and the consequences of this study 
and I understand this study will not affect the original treatment I am going to 
receive. 
I， ，agree to join The Nutritional 





Appendix 4 Consent form II (in Chinese) 
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4 .量度身體成分 (Body Composit ion)-脂肪比例、純體重等： 


















參加者姓名： 性別 年齡 
身份証號碼： 
聯 絡 電 話 ： 










Appendix 5 3-day diet record 
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Appendix 
Department of Clinical Oncology, CUHK 
香港中文大學臨床腫瘤學系 
Name 姓名: Ref. No.編號: 
RW: 
Assessment time-point 檢驗階段：Pre-RT / End-RT / 2 mth / 6 mth/ 
Detailed 3-Dav Diet Record詳細飲食記錄（共三天） 
Date曰期: 月 日（星期 ).第一天 
Appetite change 胃口己夂變: 
^ f f l l ^ l ^ m m ^ p ^ ^專-‘：：卿. I t e m s ‘ Portion Remarks 
. r i m ^ m . „ 份 量 ： 備 註 
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Department of Clinical Oncology, CUHK 
香港中文大學臨床腫瘤學系 
Name 姓名: Ref. No.編號: 
RW: 
Assessment time-point 檢驗階段：Pre-RT / End-RT / 2 mth / 6 mth/ 
Detailed 3-Dav Diet Record詳細飮食記錄（共三天） 
Date曰期: 月 日（星期 ) 第 二 天 
Appetite change 胃口 改變: 
箱n 漏 ；— . ‘ P o r t i o n Remarks 




Department of Clinical Oncology, CUHK 
香港中文大學臨床腫瘤學系 
Name 姓名: Ref.No•編號： 
RW: 
Assessment time-point 檢,驗階段：Pre-RT / End-RT / 2 mth / 6 mth/ 
Detailed 3-Day Diet Record詳細飲食記錄（共三天） 
Date曰期: 月 日（星期 ) 第 三 天 
Appetite change 胃口己夂變: 





Appendix 6 24-hour dietary recall ‘ 
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Appendix 
Department of Clinical Oncology, CUHK 
香港中文大學臨床腫瘤學系 
Name 姓名: Ref. No.編號: 
RW: 
Assessment time-point 檢驗階段： 
24-hour dietary recall 24 小時飲食記錄 
Date日期: 月 曰（星期 ) 
Appetite change 胃口 改變: 
I ^ ^ P H P I ^ 搬 等 邊 “ d f e . ' > ~ Portloi；^^ Remarks | 
餐 / 飲 ‘ 觀 丨：.份量。丨、一備註 • 
« I 丨 丨 
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Appendix 7 ( Subjective Nutritional Assessment 
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Appendix 
Subjective Nutritonal Assessment 
Name: 
Date of Examination: Time-point: End -RT / 2-mth / 6-mth/ 
1. Throat pain : yes / no 
2. Dysphagia : nil / mild / moderate 
Food item that is affected: 
3. Mouth Dryness : nil / mild / moderate / severe 
Food item(s) that is affected: 
Difficult-to-eat foods: (a) Tough foods - meat 
(b) Hard/fried foods 
(c) Fruits and vegetables -
(d) Dried foods - breads, cereals 
(e) Citrus fruits, juices 
(f) Sweets 
. 4. Appetite (reduced / increased) a) compared with pre-RT: 
b) compared with end-RT: 
5. Altered taste responses: sweet / salty / bitter / sour 
Food items with altered taste response: (a) High protein foods - meat, eggs, dairy 
(b) Fruits and vegetables 
(c) Sweets 
(d) Breads and cereals 
‘ (e) Coffee, tea 
6. Food items are purposely not eaten: 
» 
7. Food items are purposely eaten more: 
8. Do you feel you eat less than pre-treatment? yes / no 
Main reasons: 
All questions are subjected to being compared with pre-RT status, except when specified. 
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Appendix 8 Physical Activity Questionnaire 
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Appendix 
Physical Activity Questionnaire 
Name: Ref. No. : 
Date : ^ Age : M/ F 
Height : (cm) Weight : (kg) 
Health status: Contact no.: 
Here is list out common types of physical activities (including occupational and leisure time 
activities) Please tell me which of them you did during the last week and for each activity you do, 
please tell me how much time (hours) you spent in that activity each time. (N.B. If the last week 
isn't a typical week of you, please use a usual week as reference) 
Example: 
If I swim 2 times a week and 1 hour each time (excluding changing clothes), I should record like this: 
Duration for each Frequency per week 
time (hr) (times/week) 
V Swimming 1 hr 2 times 
Are you working now? Yes (pis. specify) / N (if N’ pis. go to pg.2) 
How many days did you work for last week? Days Each day hr 
« 
Research use only 
Hour(s) spent for Intensity code 
Each time (kcal/min) 
A. Occupation 
1. Sitting while working hr 1.7 
e.g. typing, writing 
2. Standing while working hr 2.0 
e.g. selling, teaching 
3. Moving while working hr 3.5 
e.g. patrolling 
. 4. Loading while working hr 8.5 
e.g. machinery 
What kind of transportation you usually takes while you goes to and from work? 
To work : 
“ From work : 
Travelling time for to and from work? 
To work : (min) From work: (min) 1.45 
Walking time between transportation and to and from work? 




How many hours you usually sleep for a usual day? hr 
Hour(s) spent Frequency per Intensity 
for Each time week code 
(kcal/min) 
B. General activity 
1. Shopping (eg. Grocery, clothes, food) hr times 3.5 
2. Transportation other than go to and from work hr times 1.45 
3. Stair climbing while carrying a load hr times 8.5 
4. Laundry (hanging, folding, ironing) hr times 3.0 
5. Light housework : tidying, dusting, sweeping, hr times 3.0 
collecting trash in home 
6. Heavy housework : vacuuming, hr times 4.5 
mopping, scrubbing floors etc 
7. Food preparation & service hr times 2.5 
(+ lOmins): chopping, setting table etc 
. 8. Cooking hr times 2.7 
9. Dish washing (+10mins): hr times 2.5 
clearing table; washing dishes 
10. Light Home repair: small appliance hr times 3.0 
repair; light home maintenance 
11. Heavy home repair: painting, hr times 5.5 
carpentry, washing/polishing car 
— 1 2 . Eating (all meals) hr times 1.38 
13. Other (pis. specify) hr times 
Sub-total 
, C. Care-taking Hour(s) spent Frequency per Intensity 
for Each time week code 
(kcal/min) 
1. Older or disabled person (lifting, pushing hr times 5.5 
• wheelchair etc.) 
2. Childcare (lifting, carrying, pushing stroller, hr times 4.0 
bathing etc.) 
3. Pet caring hr times 1.8 




Hour(s) spent Frequency per Intensity 
for Each time week code 
" (kcal/min) 
D. Exercise 
(N.B. excluding times for changing cloth) 
1. Brisk walk (+10 mins) hr times 6.0 
2. Stretching exercise: hr times 3.0 
Yoga; Tai-qi; Qi Kung; stretching 
3. Vigorous calisthenics, aerobics hr times 6.0 
4. Dancing (mod/fast): ballroom, hr times 5.5 
Chinese dancing 
5. Bowling hr times 3.0 
6. Ping Pong hr times 4.0 
7. Racquet sports: tennis, racquet ball hr times 7.0 
_ 8. Golf hr times 5.0 
9. Bocci hr times 2.5 
« 
10. Cycling, exercyde hr times 6.0 
11. Swimming hr times 6.0 
一 12. Volley ball hr times 4.0 
一 13. Basketball hr times 7.0 
14. Football hr times 8.0 
15. Squash hr times 11.4 




Hour(s) spent Frequency per Intensity 
for week code 
‘ Each time (kcal/min) 
E. Leisure activities 
1. Leisurely walking (+10 mins) hr times 3.5 ^ 
2. Needle work: knitting, sewing, hr times 1.5 
needlepoint etc. 
3. Fishing hr times 3.5 
4. Playing musical Instruments hr times 2.9 
5. Writing, Drawing hr times 1.7 
6. Singing: Chinese Opera, Karoake hr times 2.4 
7. Playing chess, mar-jong or cards hr times 1.5 
8. Watching TV, Listening to Radio hr times 1.3 
9. Reading: newspaper, magazine, books hr times 1.3 
10. Using computer hr times 1.6 
‘ 11. Leisurely sitting hr times 1.3 
12. Religious activity hr times 1.3 
13. Watching movie, Chinese opera, hr times 1.3 
concert and drama 
14. Others (pis. Specify) hr times 
Sub-total : 
Weight corrected Sum : kcal (daily) 
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Appendix 9 Bone scan report 
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Appendix 
H O L O G I C 
E e t ^ ^ M 
： n836.3 Sex: M 
S.S.«： - - Ethnic： 0 ZIPCode： Height： 168.40 cw Operator ： KHN Meighf. 75.68 kg BirthDate： 27.Dec.58 ftge： 41 Iwasre not for diagnostic use TOTftL mC and BHB CM is < 1.0% C.F. 1.025 1.885 1.008 Region ftrea BHC BHD (cw2 ) (£^aws2_ (gws/cwZ) 
"" i i iTi? ~"ii3775 ""iTiia" 
R ftrw 245.76 1 ^ . 8 2 0.886 L Ribs 12e.47 86.08 8.681 R Ribs 141.23 91.61 0.649 T Spine 1 5 9 . ^ 124.83 8.782 L Spine 62.24 61,89 8.994 Pelvis 199.48 229,53 1.151 L Leg 365.45 419.26 1.147 R Leg 355.47 416.74 1.172 SubTot 1897.06 1821.71 0.96B Head 232.99 452.34 1.941 o23.Now z酬 11： 13 Vdz7 x 棚] TOTftL 2130.05 2274.86 1.068 • Holo任ic QD«~4500ft (S/H 45693) _ Hhole Body Fan Beam U8.2ea:3» 导 H 0 L 0 G 1 C H O L O G I C 
B e t : ZIPCode： Height： 168.40 cn Operator： K ^ Meiglrt: 75.68 kg BirthDate： 27.Dec.58 ft»e： 41 Physicia,: Ina^e not for diasrnostic use F.S. 68.88% BC18.00>^ Head assumes 17.0^ brain fa t i m 73,2% water Region Fat Lean*BHC 劣 Fat 
i ? ! ! ! ! !」?：::� ! L _ 
L Brn 986.3 3683.9 21.3 R ftrw 1B75.8 3896.6 21.6 Trunk 9874.1 23198.3 25.3 L Leg 2368.6 9207.1 20.4 R Leg 2518.8 9178.0 21.5 SttbTot 16818.2 55163.9 23.4 Head 1084.8 4287.7 20.5 
o23. 1501 TOTAL 17983.8 5 ^ 1 . 6 23.2 
Ho log ic Qm-^mm <S^ M 45693) B 




Ho logic QDR-4580ft (S/N 45693) J !細： . 
Whole Body Fan Bea»i M8.2Ba:3* u o ^ n t . 一 ” � ^ 
o23. Now. 2000 11:13 H : «836,3 Sex: H 
S.S.t»： - - Ethnic： 0 
2IPCode： Height: 168.40 cm 
Operator： 酬 Weight： 75.60 kg 
IBflHlSZB ~ i BirthBate： 27.Bee.胡 Age： 41 
F . S . 亂 _ 8(18•明》游 Physician： 
Region BHC Fat Lean Lean+BMC Total % Fat 
C0raiiis> Cg:rajifis� （gpraiws> tgrraws) C grans) C劣） 
mm III »I — I...... tttmrn I'l'mi __ » • , •• 
L Arw 193.8 996.9 3490.1 3683.9 4688.8 21.3 
R Brm 198.8 1075.8 3698.6 3896.6 4372.5 21.6 
Truiik 593.9 9874.1 28684,4 2 9細 . 3 39072.4 25.3 
L htm 419.3 2368.6 8787.8 3287.1 11567.7 28.4 
R hm 41B.7 2518.8 8761.3 9178.8 11B88.8 Zi .5 
SubTot 1821.7 16818.2 53342.2 55163.9 71982,1 23.4 
Head 452.3 1884,8 3755.4 4207.7 5292.5 20.5 
l O m 2274.1 17963.0 57897.6 59371. B 77274.6 23.2 
"assuwes 17.0% brain fat 
‘ t m 73.2衆 water 
HOLOGIC 
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